Document:

<PDF>
begin 644 mt10q10a.pdf
M)5!$1BTQ+C(-)>+CS],-"C,P(#`@;V)J#3P\(`TO3&EN96%R:7IE9"`Q(`TO
M3R`S,B`-+T@@6R`Q,#8V(#(P.2!=(`TO3"`S.3,Y-B`-+T4@.#DX,R`-+TX@
M,3`@#2]4(#,X-C<X(`T^/B`-96YD;V)J#2`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("!X<F5F#3,P
M(#,P(`TP,#`P,#`P,#$V(#`P,#`P(&X-"C`P,#`P,#`Y-#<@,#`P,#`@;@T*
M,#`P,#`P,3(W-2`P,#`P,"!N#0HP,#`P,#`Q-#@R(#`P,#`P(&X-"C`P,#`P
M,#$V-#$@,#`P,#`@;@T*,#`P,#`P,3@R."`P,#`P,"!N#0HP,#`P,#`R,S(X
M(#`P,#`P(&X-"C`P,#`P,#(U,C(@,#`P,#`@;@T*,#`P,#`P,S`X-2`P,#`P
M,"!N#0HP,#`P,#`S,C8U(#`P,#`P(&X-"C`P,#`P,#,R.#8@,#`P,#`@;@T*
M,#`P,#`P-#`U,2`P,#`P,"!N#0HP,#`P,#`T,#<R(#`P,#`P(&X-"C`P,#`P
M,#0W.#<@,#`P,#`@;@T*,#`P,#`P-#@P."`P,#`P,"!N#0HP,#`P,#`U-3`V
M(#`P,#`P(&X-"C`P,#`P,#4U,C<@,#`P,#`@;@T*,#`P,#`P-C$Y,R`P,#`P
M,"!N#0HP,#`P,#`V,C$T(#`P,#`P(&X-"C`P,#`P,#8Y,30@,#`P,#`@;@T*
M,#`P,#`P-S$Q,"`P,#`P,"!N#0HP,#`P,#`W,CDX(#`P,#`P(&X-"C`P,#`P
M,#<S,3D@,#`P,#`@;@T*,#`P,#`P-SDQ,"`P,#`P,"!N#0HP,#`P,#`W.3,Q
M(#`P,#`P(&X-"C`P,#`P,#@U.#<@,#`P,#`@;@T*,#`P,#`P.#8P-R`P,#`P
M,"!N#0HP,#`P,#`X-S4T(#`P,#`P(&X-"C`P,#`P,#$P-C8@,#`P,#`@;@T*
M,#`P,#`P,3(U-"`P,#`P,"!N#0IT<F%I;&5R#3P\#2]3:7IE(#8P#2]);F9O
M(#(X(#`@4B`-+U)O;W0@,S$@,"!2(`TO4')E=B`S.#8V."`-+TE$6SQC86-C
M-CDV8F-B.3(X-V(T-3-C-C,T-C,W-F0T9#0Q8SX\8V%C8S8Y-F)C8CDR.#=B
M-#4S8S8S-#8S-S9D-&0T,6,^70T^/@US=&%R='AR968-,`TE)45/1@T@("`@
M(`TS,2`P(&]B:@T\/"`-+U1Y<&4@+T-A=&%L;V<@#2]086=E<R`R.2`P(%(@
M#2]/<&5N06-T:6]N(%L@,S(@,"!2("]865H@;G5L;"!N=6QL(&YU;&P@72`-
M+U!A9V5-;V1E("]5<V5.;VYE(`T^/B`-96YD;V)J#34X(#`@;V)J#3P\("]3
M(#<W("]&:6QT97(@+T9L871E1&5C;V1E("],96YG=&@@-3D@,"!2(#X^(`US
M=')E86T-"DB)8F!@8&9@8-%B8&5@8-)FX&5``!`;*,K`L0/"OW790:Z!@4/+
M;FI?SI>`'2R8`E`@`,124,S`(,+`I7=BT]P'V@L_-3#N<I"ZP[BR04J"<14W
MTP+&O@.2'QCD#R\`J0,(,`#>51R;#65N9'-T<F5A;0UE;F1O8FH--3D@,"!O
M8FH-,3`T(`UE;F1O8FH-,S(@,"!O8FH-/#P@#2]4>7!E("]086=E(`TO4&%R
M96YT(#(Y(#`@4B`-+U)E<V]U<F-E<R`S,R`P(%(@#2]#;VYT96YT<R!;(#0P
M(#`@4B`T,B`P(%(@-#0@,"!2(#0V(#`@4B`T."`P(%(@-3(@,"!2(#4T(#`@
M4B`U-B`P(%(@72`-+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@72`-+T-R;W!"
M;W@@6R`P(#`@-C$R(#<Y,B!=(`TO4F]T871E(#`@#3X^(`UE;F1O8FH-,S,@
M,"!O8FH-/#P@#2]0<F]C4V5T(%L@+U!$1B`O5&5X="!=(`TO1F]N="`\/"`O
M5%0R(#,U(#`@4B`O5%0T(#,W(#`@4B`O5%0V(#4P(#`@4B`^/B`-+T5X=$=3
M=&%T92`\/"`O1U,Q(#4W(#`@4B`^/B`-+T-O;&]R4W!A8V4@/#P@+T-S-2`S
M."`P(%(@/CX@#3X^(`UE;F1O8FH-,S0@,"!O8FH-/#P@#2]4>7!E("]&;VYT
M1&5S8W)I<'1O<B`-+T%S8V5N="`X.3$@#2]#87!(96EG:'0@,"`-+T1E<V-E
M;G0@+3(Q-B`-+T9L86=S(#,T(`TO1F]N=$)";W@@6R`M-38X("TS,#<@,C`R
M."`Q,#`W(%T@#2]&;VYT3F%M92`O5&EM97-.97=2;VUA;B`-+TET86QI8T%N
M9VQE(#`@#2]3=&5M5B`P(`T^/B`-96YD;V)J#3,U(#`@;V)J#3P\(`TO5'EP
M92`O1F]N="`-+U-U8G1Y<&4@+U1R=654>7!E(`TO1FER<W1#:&%R(#,R(`TO
M3&%S=$-H87(@,30X(`TO5VED=&AS(%L@,C4P(#`@-34U(#`@,"`P(#`@,"`S
M,S,@,S,S(#`@,"`R-3`@,"`R-3`@,"`U,#`@-3`P(#`@-3`P(#`@-3`P(#4P
M,"`-,"`P(#4P,"`P(#`@,"`P(#`@,"`P(#<R,B`V-C<@-S(R(#<R,B`V-C<@
M-C$Q(#<W."`W-S@@,S@Y(#4P,"`W-S@@#38V-R`Y-#0@-S(R(#<W."`V,3$@
M,"`W,C(@-34V(#8V-R`W,C(@-S(R(#$P,#`@-S(R(#<R,B`P(#`@,"`P(#`@
M#3`@,"`P(#4U-B`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@
M,"`P(#`@,"`P(#`@,"`P(#`@,"`-,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@
M,"`P(#`@,"`P(#`@,"`P(#`@-3`P(#4P,"!=(`TO16YC;V1I;F<@+U=I;D%N
M<VE%;F-O9&EN9R`-+T)A<V5&;VYT("]4:6UE<TYE=U)O;6%N+$)O;&0@#2]&
M;VYT1&5S8W)I<'1O<B`S-B`P(%(@#3X^(`UE;F1O8FH-,S8@,"!O8FH-/#P@
M#2]4>7!E("]&;VYT1&5S8W)I<'1O<B`-+T%S8V5N="`X.3$@#2]#87!(96EG
M:'0@,"`-+T1E<V-E;G0@+3(Q-B`-+T9L86=S(#,T(`TO1F]N=$)";W@@6R`M
M-34X("TS,#<@,C`S-"`Q,#(V(%T@#2]&;VYT3F%M92`O5&EM97-.97=2;VUA
M;BQ";VQD(`TO271A;&EC06YG;&4@,"`-+U-T96U6(#$S,R`-/CX@#65N9&]B
M:@TS-R`P(&]B:@T\/"`-+U1Y<&4@+T9O;G0@#2]3=6)T>7!E("]4<G5E5'EP
M92`-+T9I<G-T0VAA<B`S,B`-+TQA<W1#:&%R(#$T."`-+U=I9'1H<R!;(#(U
M,"`P(#0P."`P(#4P,"`P(#`@,3@P(#,S,R`S,S,@,"`P(#(U,"`S,S,@,C4P
M(#(W."`U,#`@-3`P(#4P,"`U,#`@#34P,"`U,#`@-3`P(#4P,"`U,#`@-3`P
M(#(W."`R-S@@,"`P(#`@,"`P(#<R,B`V-C<@-C8W(#<R,B`V,3$@-34V(`TW
M,C(@-S(R(#,S,R`S.#D@,"`V,3$@.#@Y(#<R,B`W,C(@-34V(#`@-C8W(#4U
M-B`V,3$@-S(R(#<R,B`Y-#0@#3`@,"`P(#`@,"`P(#`@-3`P(#`@-#0T(#4P
M,"`T-#0@-3`P(#0T-"`S,S,@-3`P(#4P,"`R-S@@,C<X(#4P,"`-,C<X(#<W
M."`U,#`@-3`P(#4P,"`U,#`@,S,S(#,X.2`R-S@@-3`P(#4P,"`W,C(@-3`P
M(#4P,"`T-#0@,"`P(`TP(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P(#`@,"`P
M(#`@,"`P(#`@,"`S,S,@-#0T(#0T-"!=(`TO16YC;V1I;F<@+U=I;D%N<VE%
M;F-O9&EN9R`-+T)A<V5&;VYT("]4:6UE<TYE=U)O;6%N(`TO1F]N=$1E<V-R
M:7!T;W(@,S0@,"!2(`T^/B`-96YD;V)J#3,X(#`@;V)J#5L@#2]#86Q21T(@
M/#P@+U=H:71E4&]I;G0@6R`P+CDU,#4@,2`Q+C`X.2!=("]'86UM82!;(#(N
M,C(R,C$@,BXR,C(R,2`R+C(R,C(Q(%T@#2]-871R:7@@6R`P+C0Q,C0@,"XR
M,3(V(#`N,#$Y,R`P+C,U-S8@,"XW,34Q.2`P+C$Q.3(@,"XQ.#`U(#`N,#<R
M,B`P+CDU,#4@72`^/B`-#5T-96YD;V)J#3,Y(#`@;V)J#38X-R`-96YD;V)J
M#30P(#`@;V)J#3P\("]&:6QT97(@+T9L871E1&5C;V1E("],96YG=&@@,SD@
M,"!2(#X^(`US=')E86T-"DB)I%1-3^,P$+WG5XPXV5)K_)$X\1%*Q8*T@)IP
MVG(H3?HA08*2HH5_OV./TRV[VM.JDNT9S[QY;SSI996<5Y4&!=4F45(X#1)_
M=%)."V?!.B<RYQQ4K\GY;,A@/80@"<,Z.;\N%6R'1`HIC8%JG4S]45JH?B8_
M6#F?/2YN>"X*5M$V+Z%\O"QGT?L0W?<<2[([N+A>S.??YW<5?ZINDWF5'$GD
MPFC0.A-%"DK(`OHFV22704#Z#P%I"M8J3)3*L_?,4NU)2F&DU<2Q^G;#52$R
M5G+DKAA$TL%7Q?V$=K`?QHO[$\X3J%?<.P^HR;`FG&L@WX!KSJ#C#K<-!F0,
M^%0I=OO>4B29.J?LW23:4NK0C*G%9S`I3)50>59`=15ZK3)+BJ3,4U*T9&<7
MV[[AV(6<-:\\9?'<(J*7>$`2&3OC4\.6?`+[P5\[!C'L(X8U:[+?CVE8.QO!
MZNB%?4`;L8$CZ;YY"<X]9:S:=4R"$>NM^Y)PV#5_57_E*F-O7VM3K:Z%31\:
MV7EUL22E;T<U,:-?D?\PIIZ676TV!!/&KZ^;&I[C_2<W!@<3%GQ:8`?\_<LH
M(HLQ,KCMB/C6=PB*'D]J%$J-V*ZHYXV?,8.]B^.=.U&`32VNN.!32I'^'NT_
M!SK78$TF;'HRS\7QH].*GO^]K3U//X`."?0X7$&NY[H@WY9K_"P\1Z_G!0?.
ML177U&AO[,/:45@+5UQI+_SYDZ<&/7#PT^_8C@`(-)8HR5H37"Q!)/:4=5JB
MH;`!<Q`V<FCKB#7_("7K`!FKC4%D;4>MP0FSR!F'QXATW&)AJD)K='64'L%B
MV24+=,^XRC$9_P^\?/_!6#27/%Q.$!G'N:7\>NRU"IT@A;O39X#2ST;&_J,[
M%_0*U`P*BX2CBLWI4RMGR&LF_.F7``,`,Y)*-PUE;F1S=')E86T-96YD;V)J
M#30Q(#`@;V)J#38S-R`-96YD;V)J#30R(#`@;V)J#3P\("]&:6QT97(@+T9L
M871E1&5C;V1E("],96YG=&@@-#$@,"!2(#X^(`US=')E86T-"DB)7%/);MLP
M$+WK*P8]D85-<)$HZ6@G08&@)U>W)@?'EA?4ME)9SM*O+SDS3.1`@#3+FWDS
M3V1SG]TUF?-.Y15XYU3MP=2JMJ!CI&^S339O,J,Q%!ZR2@O>6E5I;:`Y9E.M
MM/8>FA69)IBOV6^QE)4JQ3F\:P'D'*5QHD7S)`.16).S5@`WTEBN>=[+4A5B
MP#>%#FCOI:G"YQ^&N%1.C3(""$RQ/L*8C?DO]&UEV.^S:)?PY4<_IC@Q@MA/
M:Z!Y.WP3%_#P&ZQ.=3P5$-\.\>,5Z`T[BKU(JW&LZ/`..Z+FV%':G&V>A=(D
M$3M;I#G'Y<*NY!'@!>VQY,S2C9T/2E0'=8,K`EA<$'\8J0R%]O*QN<^:[_3C
M<Q?/0+1*/@&ANE95E#M^8"&GI?*A7(OMA6*'Y;#O&`:W,9\+A5V]*FJ7P]0J
M5\0C=1L[FXHZ-W):A8H=%>[/((T1,RK?2J.LZ-OVV'+C`=,,7@9VPC]1H$TP
M#+9O'%WQA$.['J6_KH0EB:;M/[#[%.N`:=ZE=6$N^-HA31'&&EX_9_E!R_1!
M?]%NNSZ5STG#N$4__.DFP15P1W*<I0Z0O]1!1:`1$Q1SFM0,/[,L*E93Y\7G
MK65E75X6TF@!/Z71Z<94XM3%X!MF%IVT!D\C;A$YC(T'XM<EYN/!\7A'?*J&
M7,>,G@`UG5'V$.^,YTZG8>R%EJ1"Z$SGOQ(X`M[M*O[DQ+1D#H<<SGH<\D&$
M9"6^21-5F%_>9>ZX3S_./$CTF(_&H^F0CB//%^9=23YW28!SN,'<%]`>Y;BF
M96"=NF'G#?)>,6)IDNSF2IU8C>UAED:B-1B^86=$VX]":_GX7X`!`%:K378-
M96YD<W1R96%M#65N9&]B:@TT,R`P(&]B:@TV,C`@#65N9&]B:@TT-"`P(&]B
M:@T\/"`O1FEL=&5R("]&;&%T941E8V]D92`O3&5N9W1H(#0S(#`@4B`^/B`-
M<W1R96%M#0I(B8Q436_;,`R]^U<00P_2X`B68\OV<=UV6+$!`V+TLO1@.$Y2
M-(N#?+3#_L;V@T?IT9B"]3`$D$SR/?*1DM+>)1_;9&X+4]=4NL94CG)GK*/,
M%#4=AV2=W+:)S4R34\8_?%4YE65M7)99:K\GL\QD65%1VR?^JRJH?4F^J=-Y
M[#43G'I*]:PRA2)O-NJ@9[SGJM/,+-11-XRAYP[@W47"`VRZ$=OHN2E5)M:T
M6YV96M'AFG2DT[8[3AF6ZM=7/6NXTLQR07&OQ4+]X["BA0>=V2S4V#]I:SGS
M;XA<ZI3&M33P1<]*IHA^$`9IYC%8W4Z@+:<,LD)4YK$5L7O91Y3:C1M\/'IE
M3@TG#Z]5F%ZIZ)/./7MB]0;^E#HIUH_H91J&F-T9HL8PJHDNG/$H1:6;*0S*
MSV&E']J[I'T;CK9PTR$W%H=\V:\&71L_VXI7.O-6^09];D1H%WQ=,%ZTS5GS
MB;-;1:/78/DD`O<#\*_`NZ@$0"E)Z#&@K\H2(#]B$7U8+W`!#>8S)(C4*T%8
M`0,?*!%OK7.6%M"V)YZ;5??_HO=Q32D3L+=2[+*+0B(G;GB5`K^XQ+W&F:JL
M$LQG/DLE>45F\+_;;^(^XXJ`I?$QEW,Y9C>7M_R^"S=IQXR")^+7-:\.M6I6
MZHT](L!2P_>E(7Y\(78.H>V`V!OMN/1">T%_$V.%!QF!6^I@$!(CDQATN`#9
M!S/<@%P4^,YJ24<'P*`08(E("^B';BP/`$,[Q$K@0LJK*@@#FFI_)0'E^SD/
M[Z@._Q&A>_`0OW*)E!!`V@U4;>+Y#G$D'D9,_]^!`/S:5![^"#``Z9%3H@UE
M;F1S=')E86T-96YD;V)J#30U(#`@;V)J#34X."`-96YD;V)J#30V(#`@;V)J
M#3P\("]&:6QT97(@+T9L871E1&5C;V1E("],96YG=&@@-#4@,"!2(#X^(`US
M=')E86T-"DB)9%--;]LP#+W[5_"P@S0DFF79L;6;$RMUB\8*;*5=L?70;MTZ
M8.@^BV+_?I0H>TY[$461>N^1E-Q9XEXGJ4C3?`7N8[+T6ZG!/27OV1VOA&8_
M'V^"_<9+4;*O87W@F*C9%RY3(1F\*M)%FJ8"8/WXEZL,S^CN+\S6#.[G'NUO
M8Q[,#W_,G=]<3SB1[T\@IP"0JH=/\,1E)@IV,^.@-68<W2+G.PE?_`>A32QH
M+F,N9J2B)A#4/4F#X6[6)5KG5;_EU^XL>>-<!A+<YV0E"JUR6&9"E0I;WX0A
MJ,P/`7>ZRFD&KC7@16DVF,VA/PW`CHP98LANMZ8W#;2XKJ^@K2\,=-;!VI@.
MZJX)W"DLI9!E48UDF28RE:<%D5UZW)R=GR.N9![!V[6!WIQ0:'"!*":Z%KR^
M0Q==C`RN=F8(A/%A*6(IM222J8Z"ZBBH#LE0*)AW5-&FK;L3`QN[VU'.,)"U
M'=C>LQY19./;E3*?6!`39^:Y9$5-"Q;9-M;'*N;!PYE'#QO;T2W@R]A9'/QJ
M<FN*=E=8)PG%:OVFFE+V!\KI![RIV:&.B`Z<Q5G,9&<RMMT7[5/,;A\G:[F'
M[$);MKW=C0-`I:ZOGR7M>WM!)PWWKQ>G@(\`&W"<-S*'-E7E]-O'X2LL0(F,
M?6!\A27?HHL.#P[84!V*02L4`X=6LI;[BDW8(V&P.-R06S'/7C'G_X=DI_@H
M/"#4FQAV+T!E5*`Y?HML$J3(74#`KX=H=\37H88,*R=00VS-(O@%\QVG2/-,
M\_4_`08`RHT5BPUE;F1S=')E86T-96YD;V)J#30W(#`@;V)J#38R,B`-96YD
M;V)J#30X(#`@;V)J#3P\("]&:6QT97(@+T9L871E1&5C;V1E("],96YG=&@@
M-#<@,"!2(#X^(`US=')E86T-"DB)7%3!;MLP#+W[*XB>I&'Q+,6.9>SDVDK2
MSG$"65X/[0Y;X&X=T`U(._1#N@\>*=I),^0@F8_B>WR4XJ\C_RY*XB29:_![
MW*E4I^!?HEOA^L9V4+8U.+OJF])?R3S.Q;;M0,Z4$CNWW?3-JO2VYH!?6V?[
MMK9.?O&GPH8+IT9G7/A.8"%,ETF<B;6%"U7,YU!6_N).!N0]LR(_9,D"MDNN
M?Y1AXCG*X&!]QD54,]K1]B4ZTWB2%TO_,TI@IN-YIG+P]9D#VF1S%HHG0")'
M9ZO><?>C"6@,`;O>5>NRP^*A+E(PW*$T[`/*E;-V8UL?1"(C1O/,$".I5*;X
M3_"MN*$*"]$T<&E+!R6:WWG'P<KS^EDFPD)C5S8,9]G8"6E7J*'TU.OD2ZB>
MYR>B<0JD48LU#J$0)9*$3_)Z1[M8"X>0%G9IG<-($AMAD;>&S@?CM]4GI`F(
M$DA9'K,@^$8?A>CZRVL;\JM0SB/#V<34)$RIH^M74AEL)KBHR47T&EUU5C+!
M1J+`0MB69D#,(S"1ODHZ[L@E!L9*GK\(&"E0U!1%E22PIII'];(X(55/D!M/
M^G&UG/,7;B9@S6K'@9PUFYZFD)^N6&V7E%R(EA?/"]YPG,:;MQ="-07IU/1H
MXL#PP?L4T,O[\5[K8C'=LB15?+&39&&85<E9@>)B.=-9FN%K*N4LQQ:_2Q6G
MXC`,C\,O3GF&Y]^`]AF,_^'0-UZ><)ZIV!\>QN_A(]V<-WF'_0_>?`V3?QHF
M_$!^&O&P'UB[]9$R"6B#$@S@`T'Y0'\8<!BB^^@281P&AO#'.Y6FH!<J+A8)
M]O;X3X`!`/U$#:4-96YD<W1R96%M#65N9&]B:@TT.2`P(&]B:@T\/"`-+U1Y
M<&4@+T9O;G1$97-C<FEP=&]R(`TO07-C96YT(#@Y,2`-+T-A<$AE:6=H="`P
M(`TO1&5S8V5N="`M,C$V(`TO1FQA9W,@.3@@#2]&;VYT0D)O>"!;("TT.3@@
M+3,P-R`Q,3(P(#$P,C,@72`-+T9O;G1.86UE("]4:6UE<TYE=U)O;6%N+$ET
M86QI8R`-+TET86QI8T%N9VQE("TQ-2`-+U-T96U6(#`@#3X^(`UE;F1O8FH-
M-3`@,"!O8FH-/#P@#2]4>7!E("]&;VYT(`TO4W5B='EP92`O5')U951Y<&4@
M#2]&:7)S=$-H87(@-#8@#2],87-T0VAA<B`T-B`-+U=I9'1H<R!;(#(U,"!=
M(`TO16YC;V1I;F<@+U=I;D%N<VE%;F-O9&EN9R`-+T)A<V5&;VYT("]4:6UE
M<TYE=U)O;6%N+$ET86QI8R`-+T9O;G1$97-C<FEP=&]R(#0Y(#`@4B`-/CX@
M#65N9&]B:@TU,2`P(&]B:@TU,3,@#65N9&]B:@TU,B`P(&]B:@T\/"`O1FEL
M=&5R("]&;&%T941E8V]D92`O3&5N9W1H(#4Q(#`@4B`^/B`-<W1R96%M#0I(
MB714NW+;,!#L^157:"9`QD0`D>"CS*-*E1FABUWH88J*95HCB\GD[P/<7ARP
M2$/@L'M[>P<,B](::ZN6PKY(NZ:F\*OXKNA>;>^U+EU?>U.KC2X[->NR-VNU
MP_*JK>G4_GJZ(+Z=7B;]$+X6'T)HR%$8BLY4WC5D*7PI+%=(XLKH\".Q:K!*
M;ZRO>RJ=<:WOF!R=^$H\=5X\A?%1]Z91I)U3\W1`=-5=_+[&?:=.<5^KHW;)
MV@3\P/1/\V]=K>-IGL3(F)]@OQ,N077>8=UG1%2*H["Q=62!1`/C+_`@=;9,
MF`ZR.>8@DA<2-Q87";K,(*+\B)+;C"]30=:86Z(-UC-#^.;MOM-KRS+IWL)[
MGGO=I+GSLW`]!O_YK%O3QIJ=Z;FFDR]]I&_7B/51-6&#=MU;`""'#[2YL1*W
MYF)'Z?0)P9UV///+-LNFGP!Q!AMSZO"O)*U`,-K%*%JF2UZ=X'/,57)'=YQ&
M)Q:>($SP."[*)(%>!)ZUJ^*(I8EY`I\D'E#86VG+6OOFHOPGDKM8S-^O\>[7
MMJDP_G377J7KK?"4?)Q2ND#/S[#BE^'Y8KW8:-7`.*U<E$PS21ARV(WT5XDX
M$%%`JNA(CI2%"8$0`#GG[H[`C[G"8X[D'4G1^*MQ"D_=2T,+AS"](/]W!`PO
MY\!'*V_3=>B'/P(,`#?L%K<-96YD<W1R96%M#65N9&]B:@TU,R`P(&]B:@TU
M-S@@#65N9&]B:@TU-"`P(&]B:@T\/"`O1FEL=&5R("]&;&%T941E8V]D92`O
M3&5N9W1H(#4S(#`@4B`^/B`-<W1R96%M#0I(B5Q3P7*<,`R]\Q4ZVIW@8AL,
M'-OI*:?.A%LW!\)ZN[1DF0%V.^EGM/W@6I*]V>2$93T]/3V+[C[K/F1YH8K"
M-M`-&9Y<!=VO[)O8B;\RUX6JQ%>9-TJ+L\Q;9<4R'/G02TRN'F)^D3E>C(/_
MMY-*YBX$(!^[^RRWRK2NAMPH6VD'W9>L2$V>F&PG96ZT#8#4KG^1QJI:/,M2
M-<)3LQ.#-V+]V'4.-'2'S*FZ:@P4D7C(A)+=#P24#"B4J4S-@*`IY(*D6I<6
M<JUT*,8$^J#+]NI#S1*[X$*K2D%3ER*.:]B.$J?66CDQ!(%74$]!L(8<;$4L
M(8<<.I02AWF!+129XI8ZXOS!$\R)9?%[9H8'DF."!P'3B'GX"2NA7IM/$SPE
M2A("L9BC:23)C;CX5]HMWLT2AR%-/"W>BP?6%>LGGX:&?KN5O[^=?O/T2FG!
M*O255\VPL?-!XF,F*[80:9R!=FZD:.65@D^\$M]EZ%J)Q<N`L<(_2UVB3Z?M
M#OJ8[+GR%'E621^42?HHBO430R]<Z+%7';Q'46'W##;>9DZR#6\E1I:D__,Y
MWK](:]_SP;MA]PD\$65JUY^WX\P5X^\X)'^2=%B//0-\'(VE19V'$(2F..T;
M]TO>:MU:Q^;3BUIZ44LO^H>>M!8K!"9>6,N+6.,BI@W$?FDA+"]ABTMXA_][
MS<GQ=(/D30IV0(]_LA/SF2\B*%+`ZC<(?T."0__$A_GBX4J85`_;.*<[S=^=
M8*W]3@:S(?&,JWS\+\``R=(<WPUE;F1S=')E86T-96YD;V)J#34U(#`@;V)J
M#38Y(`UE;F1O8FH--38@,"!O8FH-/#P@+T9I;'1E<B`O1FQA=&5$96-O9&4@
M+TQE;F=T:"`U-2`P(%(@/CX@#7-T<F5A;0T*2(D*\>(*T>+2-=`S,#`Q40A)
MYC)0""GGBM9PU-0UUS/52-<TU#/4*$I-S4W-T]2UU+/4*-'3C`WQXG(-X0((
M,`")%PV[#65N9'-T<F5A;0UE;F1O8FH--3<@,"!O8FH-/#P@#2]4>7!E("]%
M>'1'4W1A=&4@#2]302!F86QS92`-+U--(#`N,#(@#2]44B`O261E;G1I='D@
M#3X^(`UE;F1O8FH-,2`P(&]B:@T\/"`-+U1Y<&4@+U!A9V4@#2]087)E;G0@
M,CD@,"!2(`TO4F5S;W5R8V5S(#(@,"!2(`TO0V]N=&5N=',@,R`P(%(@#2]-
M961I84)O>"!;(#`@,"`V,3(@-SDR(%T@#2]#<F]P0F]X(%L@,"`P(#8Q,B`W
M.3(@72`-+U)O=&%T92`P(`T^/B`-96YD;V)J#3(@,"!O8FH-/#P@#2]0<F]C
M4V5T(%L@+U!$1B`O5&5X="!=(`TO1F]N="`\/"`O5%0T(#,W(#`@4B`O5%0V
M(#4P(#`@4B`^/B`-+T5X=$=3=&%T92`\/"`O1U,Q(#4W(#`@4B`^/B`-+T-O
M;&]R4W!A8V4@/#P@+T-S-2`S."`P(%(@/CX@#3X^(`UE;F1O8FH-,R`P(&]B
M:@T\/"`O3&5N9W1H(#,U,3(@+T9I;'1E<B`O1FQA=&5$96-O9&4@/CX@#7-T
M<F5A;0T*2(F$5TN3V\@-ONM7=/E$ID:RF@^1BD\[=I+:G%P>W=8Y<*BF1)M#
M*B1EV?\^`#XT1<[:&[M*PT;CU6CT!^#QL'I[."3&FD.ULMO-/C);^H\OFR1F
MEV>;[79+^R^KM^^'U)2#<&S-4*[>_NO)FM.P6F^))S&'<K4UA]OJC^!S4'X.
MPW5D]_DF#=Z'ZVP3!TTWU&VXWA/E%/[G\&^VO(/EW2;>ISM2>OC`*LI5L`D/
M7V:N;3=1&F5@"`SOK>--G-J=6=N-S=*<-^"&%3_H:Y?#F:=PG6^2X,JF=\$S
M_GP)US8*7#F:D`\;C)T9S]AR2AJ*L1ZJ(K1V$P7E6'<M]DT7VH@45B$9S(.9
M7`E>VJ=MY3[B3\WR@QG<:"I6[[EZ+VWJUJBGCHW!ABH9PBTM3(;50[C>L>'<
M%$LCQN*O%=5&C^I"-M=TMP>)^N%O%!UK?71@/R/OY9K2H`DYI(&_K"PXF:XR
M=[:Q+W1C**:H9.)B')C2KT>H<2\7K%5M,;HC"'`O"WZ$4<R2WD(]&&*UP6_(
MFA.=)0YZYUZ<UXS]0?F+I@%A++XZ?+TR63I_<&1(QADBGW'J\_7->TI/OI@\
MJ-L3J^$4^%",X9YOA*\Z"=Z8VYF]D/LSGX-:-C^'GOW)-4(1PQ3X/I1;T=VC
M:R#PS;&A7=`/<FC1IB3/^[%WE0BKCMX=<;2GL2O!^M5(SCHO\GA553_".*9C
MJ,_]`P0_!Z*HKNEA>J\L>PR7R<XB1A%>D=W'FB?NNR9`>=5K<,/\SO[BNGR^
M^(OW:W_S>H!?)-84/BP[,>"=N%O!70_R-O9Z.I_!97-=>%"#V>>W:(1$H:FC
M?WJ.X3[H_+*F]%W&*?9HDR%,O1ODZ=*#$YMYP!F4PR0]>L(`W2?XL/3J0_#(
M[F`>NZ*GZX6C>;#D_5#WE":6L*@3)CXLQT?"@]CEP5'S,L=5$YMYY*O9$0!:
MR0X*.N?;-NA5]`+)@DB4.PD[(I!AX/H9VQX6/S)([0(]G3A2DN3YKF0`#+()
M\[&O&15)FF%/;B^:#(]>M8_I'UY[SP=VE>M[YT/QA!T-55=^-07AJ6KH;GI\
M4[=+?C>E4J[XF/-;(/4%/=P)V?(IAQ-)B&B6PW0_&_&0:DZTWV5F':'V<+5B
M%-E-@++=(PVB#56_-.:P/UXIJ`*%849G[D/)ST]87;#$8@CSB8U1AB-$VP1Q
M0L)W+;\=W0PE,"0,]MNC>0_Z-_E51;H):0B\DV_S6RE;^)V[H&K'F2GS>VAG
M?E7B-K9PA!=DZB]=-?_GGP3X'X>5S;<FS:/-SD0[4D5-P2;)3>]6U>KQ\.<6
MA;E3NF=M4?@2;)I-CU+Q_7>!O`FY%4&[D.'>4UM9<;H(("XW#>?PK1[/@K@7
M#[5]>2X&#]V%9SZ:H0"M<2+(629*)[07,N7Z7C*=\=?#/?!>P?LX-__$["-*
MRU0$'E"TA8'>>1[<JT`4R=-"J3$+O1?O/XB#:\=!5-S/(/>QG;=7@G?W5+>:
MZC>^^)0N/I?LSJ9?4"CQ,DF\/5(J`X93:0D>C+(<Z49RR2>A?\,?A\V?J9GD
M\'&"0*^)G$^_RJXNUJ("BLY`=O,$QD:(^'6SDZ@!U5,)3;V<BRA)[8#[[S^!
MC&QJ4^/]U*;N?`]23#US$@AF1T#9!*#-V6$(I5K0&$H)#J7@[7Q135`YJ/GK
M=*WXEG![.G7@A'%&&0MI+4=G;C4U4DO=:-$2Z2"3X+4E4U15W7!)9!@5N(V4
MM6E<_VY1**>\L7'DS_O,)9?BA6/3"5,Z-D60BLN/,(G%\)Z[B=#NIPI=\\)*
MC%.^'MYI.?RI,KQAH-H%V"G#:"M_9GJ@]`B96J!NA-+%SL)<R^F24F9&[##X
M!M:=DBQKZ+#3TR+V+FA+`1?4X:/#LA)&KUV)1P-W%N?YI"&!!\W<4Y-NP6E-
MAX]J'BJ5!.\)#B[5($AZ^GI^$#VP^6`N&C:U\!)&";NC&DZ@ZB%'K6`XC22`
MS_\ECB`?^"NR2(=K>Z3T9G2EGC/FVF13KB0$$O3.ZR%,^05>K@RYV`*)NG4J
M,PPM),IM,T.H300"^/=HJ&46CE+67\%=@=:;,ZFV0@+E%O+(VIJB+$&XMMS!
M'N?9;-/[D*DH2._5SJ9,>;")CEZ]Y#GW)H-O9O\+-N4N,*')2,J-8E#53ACS
M:;*C7E]%+PO1'D-HJ>PZ3')1`N$^G7K"1PR9*N@J=8Y;K5<V=1P=Q2]NN#`R
M@.HM35(ZHZI?E#_1]CZ9:B!T4/,N^2,UQ6V*C-1*-C@QD4&[5S^"UPWXGW&4
M%+P'>`+:FKKJ>H6L&H<N_A*:DVGTF9"YG)`YQ5Q*\-\0ZE&R#8J'*8Y*3V8H
M&AJ-R`V_(<E`&U.S20B":XAQ#=F\U4TU\/R:,'U0Y)^7FAXQ;%T75(XQ*=2>
MF-XDN:ARV#(O8:+9%GMO=<>/2S]_L>M[Z9>N*D9<RHZ:OE2;"8I(+1!7M*4?
M%6Z@Z)!K[Z.*-"=27>T6TY;L7YJZ!*5X]DI#>+F&FR(_..6Z*A.W,=1NCC#G
M!K"91M7?/*&K0@R@H+<J[KU1[V;>B+ZR>&X<),P73DV!46;MP3`<54+YX>PH
M"YG[4IK[7AL]+F.BL?=IG:93GQ7I9%F4,HWAM^/QC9"*'^N60QYBCI+9B/N=
M&-D>R;OA.>C,TYB^L4_7QHF`2>7BM[L'5&^II_R4U]9_7TCN(ER-Z*GEMX0E
ML#P3BRI\F)XQ=Y.5>*C%"`RG*]04XTP;1><#IC4C<OTD)X!W[?D".>9T4LCY
M/:Q$"&8@JK:@781'Q`+;<'NL[\)3]*4X)5-QTDSOPE2&GIAS8`A]=<FDID@>
M<BGJ*0-!!HOAFB9K*6SR-54W7HP&BGLHEH.RH.HKA*G%8J02(,QF0390^QTK
M+%Y""AI-O<+>FJK'%Y-ID!*6DU#J,)9V-9%(\G</Y9/PNU\AI2!"?D]2ZZ%2
M.H`C4&UJ[#)N[/C9_`CC2%LPW)75*&$]M7:QM.E[N2G+C3Z69^@%%23:L?E]
M"YJH$=!.A%?5[!OT^:ZT>X0M3^.]NT?':*E9P%XM6W#,M-(B>0_-7-<)_'/V
M48>2_2_,SDZ?^PGI]6DL>#5S9F?7\(#Y5_W6O*A1F50XH5YD*@Z6CU-KM3HI
M(DEU@V$WKQ@,9%::[F75ZS#\-)XP8B;JY.*-UZ[*>T?@*ON^2$Y%H_.<0RC3
MP46]+.O*1U?*8FG4\>_*@.JF[&J]]MI4&3\&+EK24IT7YZ>G<5*?AK'70XZL
M8`[,R1V88XUD+\4AYYY.4(JL]H!CL<07+ON"_%(6&).V6H[N./=/Y9/*X(7Z
M`G\;:8.5\VE4*K=$TF:BM=-M/JNGE5<I4KM@Q!\GFUH:<RF-EB>[#.@_<_1X
MQ]B]U`\F+NV:)]?(9K/PH]<R5,.6CT]#CS_A?MU<I<1R:D1J3/!Q40!GV)(@
MSF,OK?E5&E;,&G%P]EX64FY;W3P:*9<IGU^D"M1A$'_P`\X"#$T9X<,Z0L:*
M1E7A,+"I>F@![:(<2ANDJ7`+^U"E1D>=]?BW:X<'<X.SD.]AO?B)/$0<M,",
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M.^]4J`9T,:+TTKJ'#8F*/\(>J[:#$6J)$BJDA/24B(VO8;#,)EIS!``V+916
M=A3]M'J`H,;K#<\-GLG*6:>:+0XQT9TJ4+%Y0GB<>^8**38Z#W_=BZAO94&\
M1MO,C`484W0CXS;#Z:[WF3?KPG,T<`E:VE;0%*O?5K\2<(K96VAJ'6I,/9(X
ME68@5?U2D,Z&6)F(XUL<!2)QWFDZ1UT)6'#YIU+A/EOL*H-TH'B)K\D?62Z:
M'5*.4]KF_HA3$O<\Z]\6K%T(:Z\,<N!V&ZFG4(WQXSZ/QVI]PH2RU*O'JR>>
M$?B]1C!H5CWTCJ^>_@LJ0B7=FT,_:>^<Z;+DUM!5MEF4O.Y"@V+UD.<B;5_6
M.M[`^=@SB#XR+O_R*L91V99KF1AN`8H@.-`[>8(?IRDO8B)U4QN0\5V>;Q,@
M+F&XQ7O73J'3L-(!-J4(<D57<X6:%05>!5UL63%B,ERZ&80#O%OVI\0X!>N1
MTA.AEPKTYWH0:.WZSXR01^[^"A%LX=_J95A%(QQB92*F6AR:1I41^O[C^=,?
M`08`M-FD<@IE;F1S=')E86T-96YD;V)J#30@,"!O8FH-/#P@#2]4>7!E("]0
M86=E(`TO4&%R96YT(#(Y(#`@4B`-+U)E<V]U<F-E<R`U(#`@4B`-+T-O;G1E
M;G1S(#8@,"!2(`TO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=(`TO0W)O<$)O
M>"!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N9&]B:@TU(#`@
M;V)J#3P\(`TO4')O8U-E="!;("]01$8@+U1E>'0@72`-+T9O;G0@/#P@+U14
M-"`S-R`P(%(@/CX@#2]%>'1'4W1A=&4@/#P@+T=3,2`U-R`P(%(@/CX@#2]#
M;VQO<E-P86-E(#P\("]#<S4@,S@@,"!2(#X^(`T^/B`-96YD;V)J#38@,"!O
M8FH-/#P@+TQE;F=T:"`T,3`P("]&:6QT97(@+T9L871E1&5C;V1E(#X^(`US
M=')E86T-"DB)K%?+;N/*$=W[*WI)!I9'?$O(*DYP`V1U`3NK.`N*:DF<D4F!
M;-DS?Y^J.M5DTZ]<!,%@+'9WO;L>I^\?;[X]/N8F,8^'FV1]MTW-FO[A*\ES
M4VZJN_5Z3>?/-]_^.A:F&85B;<;FYMO?'Q)S'&]6Z[MU4IC'YH8^UN7&/+[>
M_"MZBN)5DMQ5T3%>;>^*Z"F.5VE2Y/3YEWA5W2712`1K6AHGE-NHCQ->UK)?
M11T8?\5)RMOWS)5%5Q*SENTTHQ^KQ,,DY00V+X6VR9W(M'H\QJ)33K=1;1JE
M@_)!C;Y`2._7M9?>]IT:`$&WM%\1@7$GW;=>MOT)(=[$AAAF^UW;XUC=9*XD
MJG6U5RKC/ZPPG[T7+Y/?&@>P]P>U=S:GG<*L8=?[&+P$^QSG=^5DI1K@XG\_
M_N,FNTNW9656R5U2%72Q?Y/+7N>IWG:VW>*V87?%=O./B<D8=\+"FJ;7X]&'
M@!?/S[5K_8GI#V9FN.!#"0=<8:/']6B7U+_'JPWN3L)^L,-@O2$/../K(]_[
MYH=Y:^HLQPW^;*R;V;110O'X)TWTS&=ZE<!W\LY1$)."7!/#-]&9U:64@QP&
M?-N]V>'P5YSE9`LI;D<)E%Q,3A=#B9[2Q5C>Y%O)(MLYL^]-USNAA'V;:&]>
MVU@4G>7'Z'X/$8ZRFK,A9L5Z=(B3->6/'#CS&B=\Z:T[&>7A3(_,P%24:]%X
M/4-EJ_S0;W:#%:_H,C0J'(KU%D%)DJ1"4':4EQMR2MCNK[JR<<&J#*PK:>=`
M;J9,)=4HQZ20;0L%?$#K3A!FG`I]CK=2E04S@6$`PV7`\D7^MG&N5/R%$U6Y
M8(:VVZ6H1G0I$\A=ZZYJ@X$#9H_E`4N.Y+73O>'6L.5!1JWSY&WOK`?7-F<[
M<IHC_B5EV7#!5S]0-Z)KT@0MR>`!N56B*^;1BF.42AI&]>MHGHC)C"US<5Y1
M5SC7@R_+4LH2CF#MVA=K]JJ-TR./&CT".W<CS:Q2$CP:GV*V]AZI?%U8`^J!
MS%SZ+4DCGUDVMY&$;:$:R=@S;:5MM]<#RT5>1IV[#O;6'S^3D0GM#HYR((V.
M]1%K);YEHTKII:$,&\O*[TI/&:XC9'@>U>`5<"V_VY4*W_#@4?'R,QCJ;R)+
M]0VMK.JS_$P32&V5LF>^YSCC;D2%3W?6^H",?#BI&DB$1!D<RNEIE<BX/JS1
MO)C"G6B>O>)NV7`J!O:7V@,7^\G<7SE9Z!K8_(VH3/C'@&Z,MW/1ROZ%Z6LE
MK>BO$\)?<9YQ1=$AMI5K)Z)U\84=+:LM59B7`TN@C)T.M1P6=CJU-EUS&\"1
MD%V8;>$92,%FH5Z\_$`G[XM,"`B5A!%0*6;7QVD240NX93^K2>1'32!)JRH<
MJ5,121\$I"`K1^?[PA&-67N#_E"?K[4CG*TYUZ^4SB6;,ERG7<JNP1[]>AK%
M93"**1#FGUP(4ZVWSFI?P&1%LA$\XF8UF+<VOZ$)TK%8:PY.F@9+>C^0\:5K
M:HQMJ'R\C]])6^I;D!)0D4FAA"V+E?6#EZ`]2F%4B,:"*^#-W^`3&);<]5GY
M5<X;]['9]&J:X!7*GMLY+,DVT]O_6@LI>"M[<9?]X$W>35T<K2YPQ\>KUNUG
MGU*M-'1"0S('ZJ./6A/$0=J?#]=TAV$0/TV<CT(S+HNAFC!6CG`<^Q=NDU13
M0T>WZ*2)PCV9=#U.][J4\4&NG71=HWN^M-W1?+_JIO1CZJS[MG'RU:*[]YV9
MM6F'HKFVH91:"WQ+4RGNE73Y6"<P?NM.CXU:Q(`<U2MSS$D?EW:I1@A?[Y<6
MA@[@<K#0>J9)BVZ,%H:/;$L2_5F"N/*@/;W+BJ2<0;O&M/00[<D_E?`TR]+Y
M:78^!]BOH+BYJ3\$#Y_2(_W^0)A[#!!J@52C1\=8*X[182:;@QWU@64;&G.'
M*1.G)Q_>-%,C*CS*SU`U58CR"^TSF7_K$<KWUNV\P"]>,YF"UW65EHC,/5)7
MZBF'-4ANGNHP4HLICZ:UDAG=;U'=5$;M#CLJS@?2%^?,^:5:BL4GFKBV2P5H
MN0"T2KF4WJDI%'?N\[I[)'SP3J34IJ<(KYW;Q8?S*MMH.DD2\#7SE;_!H_,\
M`7Z<O9E)%E-'[/@=/4+[9'#C'S41?MK)YFM[UC:\"[M2Z)KG;WJ8,XT6;U-C
MO2P7OG.2R@/T_S)NQ\D[;^_'HQ;`VZ>_6+XT&O;5[Z>`67HRJO#F%.[6^`F%
M*%?W0</VT:\=UETX.K!U64RN?KSX\>M?#LL^7F8SY-PB<ITE[,3_]WBBF)T5
MW'2(-U$+D'56\$0T:"GTU4&C9^H84?%'CPTG+*=8>^B6+-07*^16(E:D8]$=
M51+3J$UDQAYJZ!(F270%24:]I99S"]R;`+]Z`0^\?7YK_62#P-M2-3N0G523
MB%7OO$@"FXB1&GGUKSGFYVBX&<C*")E9?;RNBBT6RB9Z$M].&'VCW7&J[%3;
M8;;5.^,YSSGFI,8F&%IIME7:]*OH:(.Q4?G66*'$":`K]*DBW9>'2A(-_GQ"
M?S/+!4M.PHSJS%&EG<VH8G;XD==N@OJH,,43:EZCEED5M)L_;(O4Y'9V8;^,
M$4*4%MLBF!@96O<TO[BZ:&"AKKD(2RG"+/IAC4XZ]JN(]+#%^!H'J].1YJ15
M0AUM[\;P4A#U7Q4UCC,ANQ^J=W9H*8J'FH;O-).#%L"6!P_'4AO\QVC`3]JI
M_9/1/`#^]]G]*8QA8PH/8S9%YF$,/;GXVC<>RF1%1I(>8Y9WHCKR,.7^*F4B
MM45[@_#)B<KH@=*"`]UQ(OP4\M$;\&X[]9AWS*_H&B<@,SVC5I+SRW0C%\I_
M=:'"FG@["^I``7FUG.`<^V#L(/\(%K.P$-_T[`PW*4!BWPD25?$.)/BK,HT!
MR1[+%T6P@;T@WQL8U'^%L3Q<F$=HLYR!?C@ZB>@I?(C@(E[]O#O;(R7OV_GJ
MZI_ZY9\SU`!Z`J4RPOT,#@:6H)^OQKCF,?T0A&O"F1W41E$H#*JR1*$!!87F
MR][@XW(Y4W1*B5LI%[A1DEV\CG!F92UA+/7PIP%I+_.)X;Y*V!,7Z/D^O2P7
MZ`A8S&3,275(HJM8")"'B@HXA9(AX?".7C([IRM:8YN3FM,%VB%(%Q`!J!6X
M`YK0_N:=%QV)/P:1+E(M]S^>XHO2PH^6UEE.P(-O;0PF%`N6RZ*"M39P!`6[
M4)K13H+2Z7QM:!M0FH=0<\@]?&!XMVA!9E'V6J&Z\CZ\>L""<??_<<P']4VO
M"X?B](Y:EZ6O<;Q&+GA!>'R=,[[V=<DO*#V?R+0,\\_+,)>V44;O7V-?R=(F
MD4L3:<=S\+KY=.B(:]S)%,BFN1\[WRFQ,X2&9PX7P3U-80)?$G1$&PT<\Y5#
MIKGJMT=T]%JVNCV6DC0R.Y)$+Q+S(O/I0#2_B<!$E2R$@N$,!M6K;&K,`Z1Y
MR:O96K,D/&AK7PF2F?(!XR?#W*$$-$=E>\%/:$T'9H'1#(Q7#%0Z=0<6'$.N
M3MUNXJTO3#^O?+R\4Y=P<YQ&6*%H[;-95/H\K;2G<!)(,!F_//,`T="*Y9)C
M"2HL13%9RNQGZ[<]?0UZ)-4D[QU9+\!D&.TLP7FX!+W`2UQ?*X[$A)<@\P&'
M#I'\"C`M\?PVW_K4_2$YF^2<O@)=B^BZ@,=VF.=P);#1#^+%ED)N/#NZ8-$K
M;E_`]\$M(7?K/!BG64PQM>V+#0`WI`WVI;6OIF8(72MR]0^,0S\\3S5<O07K
MGUQ_MM%X5*F"]P/D9>)4$>FBD06K8X?V(86K`X\S?R9[Y$E`W@+PCLWU/XU7
M39.;1A"]YU=,Y1*HLE0"22#*)Z\KA]Q2B7.*+RP@B5JM5@&TFY^?[GZO`=EK
M52X2,]/3W3/3'^]AW.,.O?;Y'@X4-._;JND,L=LS)T8B))E/36=(6W*R))O8
MN3>#[N@:+6?TZ*`W.JI]G]ZM,H9#WU1\EPY$2EA6(ZT[F=$@N2*_W,I>OK5&
M@2@X"9E2BKN.;M].]*#K<MJ549BQT72EVDJBZ2%I_+M80->YN+,@#!1V;=7@
MN_4.&[TXG&K2]AT7A-Y_,,F[:!#S`QKBY!GO\N^H*]N^<?A)V&@*I;U83HV@
MEK.J,16*1CA:VK#WK4WC`->A;?_6=*,!><][2G_1,ZNV7H*@5V8WXM7E_<Z6
MCIUMY%,G=+1L(\'U$*=:'*SR:2C9579R*<E8A4M,5OA[T@ZE]_^F#:CP+:A>
MN9;Z9%+46ZLKHB-7J0J3KM]%5I8BERMEX02M?J-`@:=9L1`)]&BO%;.(PJW"
MWSLZLS>%#?3BEPIJ349OPM9+T:!L\8GAUIY?\?5BBG%Z3C5T*)3AV/(*8-\/
M6=.)@QMF![I3R+:;"9205+WL;VZNLU$+OOJ$+%OZ8GBX\DMZ[)I(HM#X+'MF
M3'^M;.[H6ZCC/($*'1K@E!H%!?4!_Q+'M=O"S+^64I>;.7=Q@?`J#(I:.%%+
M>Y;B8R>0"@1WVM+^3D"D1B_*V<[:O7WT`_(\5'-CO_>`0:08F4FUDR>,PYR_
M#:;@;W];4DENDT1>R=[!*6<Y>+8C3T/;A\I9YXQK2JEJ7LO3=5X96,PS+>:N
M)#Q+`QSZL41X=>C:_LF:!E53D95(85?N3?^>2L,:&Y=UK#'CN)M\BC,<3^!C
M#C:GCLJC:!+HYS).-:X,M*5ZPWI?40#HM6]%:7(VVR^/1LR;:E+JU!%>E'&Z
MHM#M@JJ1C(WQM>>_CGVN#C_T3LA3OG07B*35E\1X[:/NAL09Q@[<YJHYGFN!
M*??![&/O_,S?'F%VMTGNH;-B-TZ*]3I\JN(L&CY(X<JUNL=;ZI,G%<B<J8,*
MIJ4JVU'Z.#-?@`DR?JDXE_1355ZQK],.+T,LAI/N>8NMY]C,!T^J+$(.*T8Q
MZ_'6=.UC)07NFQDR*7UZ<PFNVMPS2A]-SUW%^J/*EE0^&;O/+`6`D[@IM,PB
M\,R6\6[YX)!:A23M6LJ_"I&$M*;D)N+TP&<32#ERRG$/R24V['VV'9IPF:]T
M[8O34+7=TLP/X;D5\2FWQOYKU,CX4F;D,MEM"_'MBZ&]H]:M]9AEX&/@9MJ$
MXIU5,Z-RB'!TK01<2T1^EA?(HF2UB!,=7^;[J[A@&5XC"<;-?Q[+F1PDCI"@
ME9,)UG-U,!5X(BB@;Y3;VPJ\/F.JYB%H7S!<7(RNP1L(T.XY[/*$)HYR7?K/
MX1HJ;B<?)&!RG?L_'&&5;;VS3G@Z_`4@NP0@)U#G*/Q&MR`LV-S)Q2G\H0C.
M(?UKPX6KPW0[[F?(O)B7]7SI:_PN+?@8)AYR!^DEVWRDO=LQTA:"Q"T'4H6/
M%FPZH6FXRQ6(".C<B8<K5)O4RLK"@CT&6#4`E@GLL[::`A/LI)R(&Q(3R`[;
M45/B`(FF'TF430LLAZJ#60,JRUQL.%*,0H.VXRRZ7>.6,,"Y4;4U>2F-U6#^
MM/1Q6EY8G5==4E>&QE!`0:3BIQ#R"?5^CO#(&PE0ZUZT-G*EGP[C29[YX78'
M>Z]?O_ST'R^M#90*96YD<W1R96%M#65N9&]B:@TW(#`@;V)J#3P\(`TO5'EP
M92`O4&%G92`-+U!A<F5N="`R.2`P(%(@#2]297-O=7)C97,@."`P(%(@#2]#
M;VYT96YT<R`Y(#`@4B`-+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@72`-+T-R
M;W!";W@@6R`P(#`@-C$R(#<Y,B!=(`TO4F]T871E(#`@#3X^(`UE;F1O8FH-
M."`P(&]B:@T\/"`-+U!R;V-3970@6R`O4$1&("]497AT(%T@#2]&;VYT(#P\
M("]45#0@,S<@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S$@-3<@,"!2(#X^
M(`TO0V]L;W)3<&%C92`\/"`O0W,U(#,X(#`@4B`^/B`-/CX@#65N9&]B:@TY
M(#`@;V)J#3P\("],96YG=&@@,3DW("]&:6QT97(@+T9L871E1&5C;V1E(#X^
M(`US=')E86T-"DB)1$Z[#L(P#-S]%1Z3H:E+6VA6$$)B;3;$4(44(@)%I+S^
MGD""D`>?SG>^FRO(E:JP0-5#04).D,)$5#2$4RE%4U&XGR!?^!JU_RH(O89\
MU1:X]Y"1(*I0:?B`Z0S5`S;LP#,I:M9Q$B6[&QR[HSE'#B]Q.QZLDG7:H!^<
M<2\^*3_G+NEV26Z>$6AWB\"'IS6S][_E8<<4:'\A/\)@R[,FE!A3W&APZ''!
MLUD@8S]G^^&:C#;)!-^J-2P5O`48`#FI1B8*96YD<W1R96%M#65N9&]B:@TQ
M,"`P(&]B:@T\/"`-+U1Y<&4@+U!A9V4@#2]087)E;G0@,CD@,"!2(`TO4F5S
M;W5R8V5S(#$Q(#`@4B`-+T-O;G1E;G1S(#$R(#`@4B`-+TUE9&EA0F]X(%L@
M,"`P(#8Q,B`W.3(@72`-+T-R;W!";W@@6R`P(#`@-C$R(#<Y,B!=(`TO4F]T
M871E(#`@#3X^(`UE;F1O8FH-,3$@,"!O8FH-/#P@#2]0<F]C4V5T(%L@+U!$
M1B`O5&5X="!=(`TO1F]N="`\/"`O5%0T(#,W(#`@4B`^/B`-+T5X=$=3=&%T
M92`\/"`O1U,Q(#4W(#`@4B`^/B`-+T-O;&]R4W!A8V4@/#P@+T-S-2`S."`P
M(%(@/CX@#3X^(`UE;F1O8FH-,3(@,"!O8FH-/#P@+TQE;F=T:"`T,S<Q("]&
M:6QT97(@+T9L871E1&5C;V1E(#X^(`US=')E86T-"DB)E%?;;N/($7W75S2"
M`"$#B\/F313R-#.["!!@@4&LMYD\T!1I,:9)#4G9N_,9N_O!J:I339'V7!`8
M%KNKJZKKWE7O#ILWAT-BK#G4&QL&^\B$](>531*3Y;L@#$,Z?]R\>3^FIAP%
M(S1CN7GSSUMK[L=-2"C)WAS*S9:7460.SYN/7ASXVRB-LR#V;BM_'T1>Z^?R
MC]W@Y_1K_HW=&5ML1OI-=-WYQ#7S)J(K!,"KAOY[G^1,O`[(!H?=T;S7@R=\
ME(L>,S$(`O\_AW]M?CYL;!Z2GFD0D\I9$NPR0V2Y&:I-O7EW^+I9,DOH,(OH
MG+'V'[U/7O'))ZVC,`Q2[]8/@YW<'[/:@=5?0%C?V#.-@%BD%#H0K)2/J)$J
MWIFMD*YAP)Z$`=CH<6>.%USUFQ]'S'A%=X\-R#M0?I$-)#OB+I6&+.IO6748
MU-&UBVN58'TE>/V*HZ662X$['*M$YM(=5\8!Z@E(.#&X!4(\^S8BP=1ZJF3]
M;=K;:4$\J3,X#.(@VF<[L[6!W:6Y.?P$MY*KR:^TRB*+H.YK\Y._W0E+0B&7
M%L_%4)F"--F3*$=\3#.:1D'FON\=>)Q>(#9D6S8R=F0'8FE$))L&84II%;(T
M+$R:.F%BS3`U5R[FRHD[&<"[^*%7"O1$*S%7)AKG;*Z8(E_0C&X:.9_D5PB6
M`&">P1X'W<P>^S-8XQH#<7XE'*R`R2*!(6@HD)SAMT[-%Z:W*"B\HH2$Z=E&
MB5?7;#/+S"OC2V"V"J``(.YE(?%*.E1'D*@K:`'\2?%/@%;FUM_F4EGH:BHS
M[MSQ[VL!9([^/4=`Y+E[VJ96V0;4*KVM47:*1N4PHWJ@/,R![TQ?R5#Y7+1:
MIU(U&,4HY&`T1=M2;?I,58;W%[UJ=$91'9SHI5X.TPQG)>N'5TJ>P4DU>?9)
MID%<=/B[)D.D'@FS/3R"6-XAEDFSXH+%=,*W'YKI-S^*)1U[TS\K_@U;@DS0
M5L7H4N?*I3]C49&,E6FF<2G@#C8FG\Q84U.-KY@4XUA-H[OHY2D)4Q;#X&3K
M]9@O6ZL\:[R#QG>,F,+J*:6'U+8.NXJRQ3*4+C=GP`86G>KJ6"G2U#*$JR1=
M336K[/7@Z#@SBU)#-_U>T*0N:+AN6ZXB;4OATN`"R&8^KP3F&"(T1:D;=PL5
M2X'T<KM1J.[NEI*-L[;":E2=6>7"U-`6=$/5W'=K:[H"%NZT@)7]<*909#**
MW(8(Y;VW4H;VR"3>5,`HRI/Y+T$B!#Z=#%J)J'I0;AR;<A(R!?0=9;YY/C5$
MQS%IN2P))XI%WR;</2B4!(R4&UG.`S)D.$,&$8X+`3<M.)GTWFN`BDB"TI\I
M,@6+7:WD>F9PH!(I-20I(`D05,=J;44[!V4^OTF<)>*G3/R4.#]EXB=JJ$:J
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M[J/`#CC41>V"W`'IB?<>L+SQB9&@_#7@H4&69R<UMD]`+691+_I@?:,/$\OF
M:MDT4M.>N;VPTO=POV316\8PU$[:'7<*3,/.H.\?G('T@O/=>\4#*7[)#C"!
MZIZXCP([(]KOW;X4#@_8_"D;<K5(!>872`0B%4]I!VV$^>2+($/6(["4`?7?
M6)S/P[7)U\YZI^0J)!!Q%WA!3^G)23GJJFYLE-[$^=[E#5DU=@&KG%<BC]HK
M7\W5'7%G=P]T,?_2D@)07O750[\LO0*[G>0@MC?RI;B/_B&L%RQ)_97MJM>N
M;1:"TI!V39SOQ(-BKZ6\7=JL75@1E)1&T?6B5R&4N)-W"]M>'[W8ZJ,G\06/
M6?<14"=J2WQE@)32>'-T46YQLR882"[*JUQ:?TXBPVGE`=(*/;\=)+W,!>=J
MB4I2RM/C+1DH)F4)[_Y@32-D2:9X(RH&J6>^H\$WI/]3EI09(@$8BH1`%W&$
M!M(T`OTB:)#LN+2I,VF>:EMVG53)/,L(2-T`6"S&RFK.]^O0>`':]&I.=:QU
M7G63:O$5'CIX_K*\JT08&HYQQ/=<&V+$]JLI=2FD>2VW2>?7X6H3:W,U!2+Q
MA$&DD-K.U)%01WI\S=!$I(X`N04.S7+R7RVH_^9'X9K\PY)MO5@#OCP]NL#.
MW:6EP!^PH6?#23"']I61A+;6-LAV@7+@;<[+6\T/U,<S$'E_\3.R]_^EPC?%
M!R^*;?;&SX=-DD4!-;C)CIK)W&14'B)#>#EU8)MZ\^ZPX6:'0/2'E<U#DV0Y
M$9'NA\=%V9"&S^8NR%]E#27,5[+&[A=ILY5H$Y#D1R@UB\_X/;&Y/N3\G%CE
M\.A'2>#*`ZZJM+(0?B:OB6=BIHIW-PE_=Y8L'X5?JRMVK\6#TB2R2_D9.($E
M2#C+9"MIYJVDO7*H4406-EA*"CD`T=*D,IBCPY,[H%)@]):WJ'7MJLYHJVUS
M=@?[H)&0&*4['UV/'DJ/R'%WQ$:R-F%[2[S,2-."&FN'"+ZH+AFB.$,4)XK#
MP>BNP;%C7LO)BZN`KKU,!DOLW$>!W57.#TOV]6(-^/(4F<`3#KB4`GU0R4]@
M^80M*,P=OOA],1.ZSBYTI5Q'U4EGW'YHOLQCJK0%.H`N84]%V^B^E3E!X<TX
M*KL?LBB&2KZU$K0SHS,`A0R\[AKSDH=N>?I(/=ULT5T4XUB-8W&GC-E!U%@$
M/#=1EV<./&7(0R6"FO?^=D=4BD?$YNW29-3#S0.@VNP#Y13*%@HC3ZE6)J[!
MK?P0X8GRO960E_&&9TUIP/M2P)GW0.&WE<IV`G[1"A?*?\R8[$F@FK('H,.'
MW"Z7X53%F1JBBIA?6]&P:"5+BTEYRK@EIQ4U3J1YQ"$L`'&`D]UI\KM^1U\$
M4%6JMG+BTTRZDNE&[:R8C8(GQ:*Y4$_TX(+/(Y/%WJRPR(`1IJ\=R>@LM-:X
M&K\6XS8+,^VS:PDU=31"YM%/)$\3'6'G(,+;R:Z*X2J:/<J'62LZ+(NV=%%+
M(^XRJC7FECF!*QS^U)S7>=/HM?=FFB-204H#!LJYDJP8#*FD,BH5Y=/(T!]$
M<YA%\T,77:.9NZ%ENUXOUH"[4QGGCM^;RIRSSI?5Z+&<##C@Y]G"C5]W;FJ:
MYP][13+O+GJ\GD0Y/F;"R$V=C;_EAR@`;B!#"IG)^^:@(H/&<E+1H3+PZ>5]
M6T^O9A,#K=R4^K0\`X=F::#N9AVAT5Q2=!2$\TE;N!6.IM&HI<?4,F<S*D;1
MMOJ$'I4$F,U3->C!4)UQQ(6$.XNRHI<HY;SJ<#`A3E`_8^_QD;YL0CUV0DR@
MI_A7SF4U3$W=E!"*@G\T4Z]G5Q7>@?<%>PET]ILJ\MPXS*9;36[Y-3(MK&)#
MJH!BP`O\Y4Q+'045D*7#N`WA&*"F(V)[:$R,KJT7(,+:>5-`ZLYGUG]'.[L/
MK/INTE^Y#'=U&JO0N%/O`E&E0F!HU`)O/?66N'@.'>JQ7H3U2DN'M[H9`JIR
MJKI*J/(:EZ#"_9I3X?_X+IO=QFT@CM_[%+I5!KQ!+,>6?5R@/13HH<"FI^Z%
MEBE9K2(9%.WT.?:).S/_&4IR@EX2BQP.A\/Y^%$B1BS(ONF/3B:[19"+'WX@
M,70?PT-)VK.*?'8'E)#S!KHSZ'@NBWFT'RU42H3*$:$B`"EA_(3^E/V)>+I"
M:.CQ7ZIK\)5O=2*N)':I"$[Z4]T7"B/=%.JV_EODP*YL-PEL!R44UZZ./JQ$
ML+(E=U&APV-KPVNU,UZ4)C3S!$66B2^N^"O_BA-E?W">E=)LIW/7^A6PC^=+
MVR#;CYJ:I1YVRLQ1CTSP()D/=$BK+7^=FESA6V<[3^AL;H'FY,$1>1MQH&G#
M&%P_UN8BN@<I(70C:NBH<F^N[:-K>S-G*EVT[&3WON47T'1O2Z=M4K74IYGX
M`)10<(T,/Y1NQFR42V7C6!5Q"YF8N<;K9WP2U=0>BB/A'(7W=K<A3/B%M'[/
M*RK[7XK-D1W\"C]?YD56C^3_U4&M@UKHF(065=3U6J*S5*I%GFNU5D.T:2V1
MF:ZO,4KN:*E]-\&K-)/`K(;#\ZH:A=P*TWPLKE<OQL\EM>Y4IZ&4HWO4$V`#
M[15.COSA4$/->Z3+*O6RS*&DLMP=V*'(?<0[Z/.(\Y;I03`Z4*3XSL96#".9
M32S83'G,`XF,I%3W#,6,I%1'\`]<]L[I1V6>6NGB'6%F"NT=4N+O<"-EVJJ%
M'57D9J9CNJ<M'11>"<L2^RV9>/:H2;R(^7L[$%BVJGA)IT/]@!*[Q^(ZA(D/
M-L](\8).<"2S'#YN,M/)LS8R-/'<^VI+M]Y&&;V(A`0DJE,A/?)%)"X#%$"4
M74@?(AI;*2P'JAN+I=A*=[^*/-<5$ZM5#`KYX!R&'JJLNBX4GH9X^;Y:`W:M
MS=K!F_;.LGKR+,CQ5.NH6HE;6(:?(RC_;</?.'<TC?7GV+8I#=M\>&LU,YS%
M<(D@.-IK00<KWW4S&9D4DQG0:-*'#[-XMY@"JQ(R=5+":YOY*M)'/.:R;ACE
M->"R-TJ+T%)7^'_2.BD]S/%_3D'KU89VOO7G.:=@T,W)R%#\"@G%CSL89DXM
M2SS^%)0>F$6`ZJMQV@1RT`3LFC.,T<A2Z6_`%C77*%ZLA-(K9G05QG#$!>8E
ML+?SGQ=\].`.#%)AW4K;$NKJS^E[MB*JCSY2`ZTI#@_\%'P<UBAFAE+*4%^D
M._Q.[Q?W/II(8@?KY:IGZ,X+6@C\:A1":81XJ`.]>>W@<<P,(JR+V[=NG;DD
MK!)<KXM\ID%*X^(4&.*(7TS-P[:<-?\]=V1I_1SS,.```RBI+>BSMR'$AKH_
M.R#/6A4[XQ]KT)&(LG+#%Q>9W)O3.N]&G^KY`-.P6L=<,SGHD$<5U$G;=(Q!
MU4^2V'6]R,T2=[T]%'K>*\4'QR'"!YESD#CAVEAHE5EI2!9YS[]Y#2=:H7^Q
MR"3XEFEQ1CDAFBD\L>P".:QA'>NLDQ&,FV95,!?[^W9NH%W-%#FU,M.->:^S
M'4=LEZ]*1[RJI[K"807U4,$6XM<-_R`GK<7FWS\OUL_[HS5&9:46@-U/E5D0
M*2@%=49&=(4!L`/\:TS`*1//R[7D_A6?^J_#/JVD8N5.#^HIZ,%P!E+T(..(
MQI;60]HH!,XU%6+*C,/5TY-%=8U9:G[TY/!0RR2US9\D]+-7VR3XY>-L`T(C
MTE1$9MY@8*SL>'NR1?`<)$,-.O)V5WP$Q()0X@NY$A"VU[C?YXT)@M9UU(3(
M9AMJ9%\[-CH9OZC^,;O>.],-4<`#_:AA@A+IGAWY^$!`_)ER$PR>"H6J)]V+
M\"E3C]SN$#^N<7R5+[D`CZ26`$:408.W>-%9`8U]&B>3CC;6=?HC2)&9%I]\
M/:SD)1.\5#711&6M`([>0M1*A%8#)2";DTK#1GH!P:XA5<B%KF:X8R,?>BE(
MFX]',8UJTGFI8FW%3\]B.BIJ>EO>0K4,81EP^P2L+YJ7=<TV[_*JE1-IXNSR
MY!S:YAUN13:1*+M^F]L@1(9;=[:!B[M[*!/$H^8K_MBAQ5%CAQ[J$8)8MDZ<
M<DQ"8]+!_%SFM:\P$&%A-D"^MVTY@[%-^)FIHD20<#&A?-7CR9MJOLQD9DA8
MM[VS:=US1G$(44G=9SBQ&AXR:\K>)WV2R.)?7W_Z;P`;NA5M"F5N9'-T<F5A
M;0UE;F1O8FH-,3,@,"!O8FH-/#P@#2]4>7!E("]086=E(`TO4&%R96YT(#(Y
M(#`@4B`-+U)E<V]U<F-E<R`Q-"`P(%(@#2]#;VYT96YT<R`Q-2`P(%(@#2]-
M961I84)O>"!;(#`@,"`V,3(@-SDR(%T@#2]#<F]P0F]X(%L@,"`P(#8Q,B`W
M.3(@72`-+U)O=&%T92`P(`T^/B`-96YD;V)J#3$T(#`@;V)J#3P\(`TO4')O
M8U-E="!;("]01$8@+U1E>'0@72`-+T9O;G0@/#P@+U14-"`S-R`P(%(@/CX@
M#2]%>'1'4W1A=&4@/#P@+T=3,2`U-R`P(%(@/CX@#2]#;VQO<E-P86-E(#P\
M("]#<S4@,S@@,"!2(#X^(`T^/B`-96YD;V)J#3$U(#`@;V)J#3P\("],96YG
M=&@@-#$Y-B`O1FEL=&5R("]&;&%T941E8V]D92`^/B`-<W1R96%M#0I(B9Q7
M39/BR!&]]Z^HH^1H&"0A!,=9V^$('QP3,?BTXX,0!6A;($82S:Y_O3/S9>J#
M9B9L1T>TJ*K\JJRLEZ]^V;Y\VFZ7+G+;PTNTF&]BMZ`__(J62[=:9_/%8D'K
MYY=/?VY35[0BL7!M\?+I;U\C=VQ?%B22)FY;\*]5LG3;^\NO@0M7J^!;$*[G
MJV`?SA;S./@6AK-HG2WF:;`-%_-U</+AAI;=5WPK$E[J?\PTHNY*F6II:ATX
M?&Z[WR!2R/].)!P^=1BQ=1V=X%Q=P2(&5Q7$'*3AZ@*=HQH:*WV_060\=PZC
M9+[1P:4;1ZLN#MC(UX\QE^.0+ZH5)8Y2%063`#$5I9942N<P/?4C4P_;_]?V
M[R_)/-ZL,C>+YE&6KMWV+R\S/KUE?WHQ#N]K.)/=%;=PQ@$U95?ZUN47#/?X
MN+^RV#KX'</BA*])';W[',XRBJ$(%T$WI]^!VT)%1;W[`D\-11SX@V\:;\8U
MAHY6*/ZZ>,.N[J:J7C!;MJV&:OJOX@XJ957AUTYE*)X?Z>G\1?*U_9,D*$HC
M3=!BM4&&"A+CA%/>:8/G<+:BJKZR":KCDA9CR4.\X./V3J0W%(FL="<(VG1>
M53+O<K6JALR>+);F,M^-IVDOE!ZS]$].>!S,.9X-'V.TH?!TZ`Z\-^R?A/8:
M'D:-^:[ZJ"[P8W)T\W@!1Q+D'=SWLS!C0=Z@V^B&\:$2DNQ6YNO>4FA1QFGG
MRHA817/C5<3YWRW.!]L2!@SC%"9GMEBN[<RR%&>67_9B(:%TR0YMZ'F8\KEM
M:/2NPX9&:?!'&,?SS#1VJO%'F"0\VXG&:6J'KSD,5K+L88FQ("(E/@4>PF)W
M@M>6[VD?F5R<#0,0:S1JSQ/0+*7VX9?J1>8OZG__@WA@LVSYFP7M+;\4MM3'
M)!$^5_]B_C7R27YL[2&U7_F,&(/88%U`YLT.B$]EL;3SB1.<SYT`*PGXLE[J
M,.7<N")<4G0873JJ41Z^R]#+[PL^#B)-**<RT6IIL.$*I-2E07?K5`.VW![#
M`X:WJG.WB\XU*D/I36DO5`E\)N[:4-+X/B&.$@Y*=:>1'!`)#%RO58F8,-[!
M8*615)C%]ON=3&K9\"?*ULA5XX]Z#:J\*VN]JG+1&</HDLF_+4#4[I3,";`N
M];Y6E6]DMFSQN1@TT:"HS^%RC&L&"81H][)'L1%0R+BP<`Y<TX21#<RTY)&:
M]*#YJN$^&A#`[JUT%M/-D&%412O-1U>[QVCIO)*IOV>1'BRZ9W%1&*TV0<&R
MB/H8-\(JO[>O"JIMEW?^@V7<@H/?6\S`V,I,UXVN,(`%JIR+5)]C<C%I0DD/
M:)$6@?8N*B0Z+8XHH[(BND)Q<H\[VKJPBIR[<"D_:VV>[2L'XIN642`.>@.P
MUS60+JC`PBBVT-9RD#%*Y)$2R!RW6^8DW8F*"\XEG!R_R?YWC:Q$K&="M-:I
M$T89@;;(_,E)DL-]??8::D<7ZND-R6*MB+IQ=+:^/%I%'^MWW^C@[*VXQ!G)
MV@%:U5C1419NSW3RJNQ,UNK&-[X^H,6=QB?Z;L:.TJ<@\9MTKKZV6JN'8KC.
M2NW>^8H*H^M[XWCK:<Q;EY\*I(6@>A)<]K>"6>!&<3X1G*?]EIB5AD"0L[NU
MI4Q<PA[W(UO5C^>[/*BHO0;VE#'`ZFELQ`3O80RTEEFHJ:U3>?UY>%>(U]>)
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M=UH\3](H&]YI'RCMM\#3,W`61QO>[);@9?5(WXR@N6<\TYBCTD"G!#-'CCHM
MM-E`][A="8\!P<7(NIW.%LI.WV#TP<>=F!'5IG+-.EP,!JA?3.GC`X^V>IWR
MYUS=G7(EN$0?=6KG_90AJ])5AS?Q;J0>7DHEJY5Q_+T1YP*)J$:!ZXJF:.]V
M?\@!VOG126?I>CB_N*=Q6F5`]&S,S%(A"]'`S*@Y:8F4J)VVJ.K66]F46D;N
MSH6J@Z,C0C08_X4;>QIH"4K;2M1-X^XJ5A;Z@VB12E9P:*X:G[>U>LBU]"NU
M9E<!5N75QL.KSA:=W_^`MTU;)5$I!T*&B<XW95ZY7-OC.^.BD=>F]<X?#F3<
M]2VS[Y&NJ"$[96;EJ+U^"P[E4^HE`W9;,S]AZE$/O5<\W\N6;AX3AX^>1_OL
M^;K/C7J,"1_X0&ND<#?AN:#+%J!O"3$.A[QL>G$ENHVR[*N1$($KIC1MZYE6
M'49)^4#^!T)JQ[Z28^^9['#H*SWT$;<67-T]8R7)NB=DBE4HB00ED6A)R$\N
M5CYSX:B,.W+F<)(9:T\"D\[U!_&BU@]2*`1LE<P[!,L/2F5J_$P\C`0D%Y'D
M(M7K)FVBQM?BE.5&WPEKW7/9M9-RUAY?B\\E/96.!$M2.EIN2SG/E9[:D@Z9
ML;II;QCF<M@JV>%$#>'L)B_YK1FQFOM,%UJJATQX3ZB=\B4S=7D&DI3;JIY7
ME%@&![D4I'7&>Y1O@SMH$,UEZL:T);8]!DYW*!E=#2ALCB2IL>I42$&%_5""
MNWK:=HTC;31_`E0);D`*'\!#ZN1,YY&]U`2D]!5D4FXPS`^\E#S)8L]I_R!-
M`_WXGF,;7["WGXUM5+88?\;+Z"@>).-+KGBUT2E1UP+*+Y/PU6)CTVT.]Y.W
MW;+O[+%R>-8"ZYDK7FQ`'J@DSU>,*XQSE;7E/5:!K!MTIXB)`,1VF);P"*I5
M&HXH>>0K7O03G66O]V[>2@QU46_I8/:F9DP9SZ@^&N9$#V'K`XMDZ3T@/P[H
M/]P2<@(%?C$-C@F>#Y1*F4P$P.HSO1R>O@K'_8;)F#>3I5IQ!K,%`6W>/+X"
MR?I^@O\"6?F;'T&KV!T>B:TESAZ,/9*+!8/7T=O1!%['R+)<]:^[2$E#&6:@
M50N\33*A!AF>,YS;4R<C5V-XH!$)8O($-8^'3:$/FTQ(+(MAYD:00B1&.#4?
M4":<3U].BU[,ZSM-7FW"N7D,0TZ>,*DYA`^HG9[%0G0KEK,>V=`H-1BLJ)-7
M=]'MZ695"'X0$E(#>54>!Z-;T:3]E'I':=I?T,2HMU1>+$7*7R'BR8+=_(/A
M8L4W*!`*)Y40+9@N1H(:]+M[=;GPT.#:U.]"G==!Q6<6@^(2Z\AOG;!Y@A;:
MT#HH_RUD=X6F0O,@B(>IUMZWY9$G($,8+SH<#69>@;*BO)<97U0BDS>#`[Y1
M+'&@!BIS4#[RIN[\3J!&H>&)7([UGS-@S6*RR9#%8TU=7('QW.,I#H:NIMA5
ML#=,KAOMYZENOT?R$7"#4&MCR-%`NJ']I]:I$NTNTOX)[1O_?=)A2H32`%/3
MX+]L*J-^TCM\1G_?\ZHT)``_8@A2&C9BJOG%I"8P5)64/<.J$<\K0RDV;L%"
M%4@45)-;5X]0(^K'7"7HD:PF*M43PY:>L`,/+MM6H\N-+/L)PYSBKYWW*HZP
MX2^<]`RE2E>!_#1]N_J*-6T'=?'&D?U/"J]HT[(C:WY#_VKE::)MZ'S.+;\;
MR=UC_T)+[QYZZ+29;YXU<RKNGOK^I^]J66X5B:'[^0IV-U1Y4N%A&R^G<C/+
M6>4'",:8Q(.9!B>_/RV=HP8<QQMLA*16=^MQ#F%-91B0R*X&^B(4)#PJB8=S
M#FX#7JY>0JX5T1WR)?<70#]C-,$P*5JNV81LS!^B;T#M!83@&5G"4YC07N7I
M1&F>%F<2PH-4IQ_1DC]-`*%;$/EOK'L&>,5!1+\%ST;2-OEA;)%7C!+P^#07
ML4Q\`*T0'L.\-[KX9NKB:>CBLR:>Z!#X4WBJ]G"/QOS?5UFF0%$8K76U](@.
M(@E4V(@D`"3\L-+-]'AQ:"#GJL;M;LGH_+".`!AU(%'V60^C4`=FYN0&ZU.X
M5V@U\X05SXI*1HL8!R6-!VM(B_L5*^(:H@_;Q-?)XFIT/_7J7O^VU$X5L2J@
M8C)XFC@:`;$\MDPMFY!"($'C]SPD89`V_&5LI[*L19:TJ)/F:.GN:J-/IS%4
M1<CUV@76PWCHX+/E^X)[D6\JUB/'6Z3]E/6W$&;RM&9*E4WC:G^%M370=FKB
M^&,-6W:%X922\I+:;D!MH^JX;+5-/3F;<.<;_K`MH^L'K#D,%D8/B<,9G(?>
MILT85`)@913M-('@=G6SSR7)9LV]'PYEZP;%XKW=0LAFN_UI7MR\_XF]HC7=
MR10KQMRZAH?U_?Q2W6B7ZBO#1V7YPH[ZKM5?R"%,I9,O1_5ZPY1/M\3?O5,L
M>48M?<9D0X7B3L62>*%"IZ7++T`L^'``NE6,$^\46XN*!\+9E:8SY+M3:*SX
M-T[-^$N0[YIR+#WJDSH0P?G[I:MBD+E"2VH>Z"IZO^P;O/PK"$\.6P.#=K0(
M)V(\U2PJ2/",EMN\M4684N\"%]=++:HMXUT\Y<4U?BP,/Q8`!#+,&I-4F@:I
MUG9+V4!*^MW0@[*1!H_:6:/Y,"B$JX74*S3U4LX!BM"/,1>Y1COBO<>KX)EI
M*!0/%E3#";K<=U8$'LM*@WYV/3#\/'K#K\:_M3Z16?DD6CYKE`\FJ$?&KJ;U
M>#*[GF:JS:][_&@;W9I0Q@:&SQ>78M_.[B]N.QCKI7?I$5NMUUD3SJ07^9[Z
M.#^6)'`R@],V3OUU)3MPSP76?Z'\F02(W\$/!K,FB)=[]:S#W[3*U[S*]4/@
M`J5^V)J!D9*SPX!>DUM8V_$>Z(F\Q/@._9%K=#1N=/W(8TUS9]RCT<-3T9+/
M)+L%H?DU`#YGZ/H>$QRTX?D_;F(T>LP\H-'0RL>\!>9;.6C-Q)2-/O9Q[CUM
MV*(J%-3&`LGE>5(QGO+N"UNZD+P.ON)]L71G\`DXB"[=_DJOXZB&FGR$)0R@
MT^"CQ#(7TW47O?DVD\IJ-\)\>6:A05E7QIC_IJOB?WY:I0S[A>)?B!-/*ODV
M1ZL?8YT'<UCVO.GP,Q:_ORQILHD,T^KBVECA$'YJ'31%*(7?=0G%$SZ[6,?Y
MRK[S:Z>OZ</>Y*.J'RGF8LK"<GN+2CBK([/6ICVMW3L**CG.8,>?/8T0M[EH
M8#&(1:IM:!Y`"#-^TJ;91%R!D?ER<%0ML8.ZJ_?2$^=>#F9D&V&\?&W%U^:G
M$[B%_J8.Y*$?@=BI',_.H!XQFK24W-`5OSW>8RQ/Z]U4>IEQEJ-6<4ZVHEY>
MM;$>:XW9Q0E@C*+7DK)"1:E<!.M/H%B<8J^"K()YH:@W410@TP`NH+18HHW!
MSD!C"YVP\'C!E<-FT#P9J:PA='O8=@WT@28\,AO%L_KA@8=@H/#?!8;4TQKW
MYE@"*A668`CP8$:%9IR:0AF&4;\XM+FWSG:B1MBEK5K%`)^ZA>[3\GLZ15IA
M];<33_`.P\H#1=WLYJ/>8[HSNOG:.&5]"&W<#TRR/84P`BT^%$=+_Y+57E[_
M^!_&;3J6"F5N9'-T<F5A;0UE;F1O8FH-,38@,"!O8FH-/#P@#2]4>7!E("]0
M86=E(`TO4&%R96YT(#(Y(#`@4B`-+U)E<V]U<F-E<R`Q-R`P(%(@#2]#;VYT
M96YT<R`Q."`P(%(@#2]-961I84)O>"!;(#`@,"`V,3(@-SDR(%T@#2]#<F]P
M0F]X(%L@,"`P(#8Q,B`W.3(@72`-+U)O=&%T92`P(`T^/B`-96YD;V)J#3$W
M(#`@;V)J#3P\(`TO4')O8U-E="!;("]01$8@+U1E>'0@72`-+T9O;G0@/#P@
M+U14-"`S-R`P(%(@/CX@#2]%>'1'4W1A=&4@/#P@+T=3,2`U-R`P(%(@/CX@
M#2]#;VQO<E-P86-E(#P\("]#<S4@,S@@,"!2(#X^(`T^/B`-96YD;V)J#3$X
M(#`@;V)J#3P\("],96YG=&@@,S,W."`O1FEL=&5R("]&;&%T941E8V]D92`^
M/B`-<W1R96%M#0I(B8Q72Y/;QA&^\U?,S4!J2>$-L'*R+%<JN40E,2<K!RP)
MDM!B"1H`M;9_O;O[Z\:#NW)2*BTQ/?V>?K[?K=[M=HD+W>ZX"H/--G(!_<-7
MF"0N*_)-$`1T_[QZ]U.?NGTO&('K]ZMW__@<NE._6@>$DQ#.?D5?85ZXW<OJ
M%^^+5W_QG;^.@FVQV7H[?UUL,N_LK[?T4SD_#+VZ[V\XEQ?\[JL'?YUM"D_N
M^[(!HET?\",P_:[\8!-Y3?VMZG[WHWB3>*X]NF&4\Y'E)E[GDYJ%5QVKKJN,
MS6?<#?XZ]-K]DU.B4ECV[E%Y5"K=*9WJW#"9R2P5:(+;KOYCE*.,?O?_N_O7
M*MY$VRQWZW`3YBGYZ@-[K8C5:V73N*[Z=2&H9D&3UONVNYJ0<JA<N1_JUE0<
M/R8/7.=6=</2/>H"]6)3=>;_>Y>_&(D)F![/-!/2K>?ZMC&JB0N;OOL;V1K&
M109;!2D5V3%>L%*0JR_Z4>[)7(66"MQ7[J6&":D92FS<4'7/O3O/N78564ON
M"T=BDR#`D7;".[;=W1V.^U89],0X]6I3GIZ`O:_F22[P6THN9&$*2ZO?&#OV
MKOB18"3:OH?!L0>M8]$Z):UA?VP.C#W#&PQQPA&WDT4O-<7.XYR/4ZH;?AH6
MFR-D\]>LOY5-K=^-X=@CQYYI*M+H98_&=,05-ZF%Y<Q)L3=_@4F>`!76^B&Q
MT,-ZX<TD4F\&V59SA/S6]Z68FDL:;D*OVFCT.:DT.2I-SHYR)?V_X,B"2/85
M)WF(K5>M?:IYQ.-9X0,%H^OJD_(8>DZ:4EF(O<2CUUOBKE\:][FXGU*6J23!
M4H5P@FW$NK65@6@3IV'.90#6IF9M'ED=_4H61I2D7WRJIG$:47J2C5OO7/=<
M"-V/_CJG)SGY(>5WQ:90H7OVPY1-(J7#@$J<I..Y!,6C``WUX@XW`=!3QES+
M`+_-*,_RW79T*+SZ#R4\/+#DB$*'19?L3"HBOM4L4OD@T<$%6_S\6[5?\A8D
MU>,@,$4M+WH\5`N&(JF"I.XMPO:RM`Z:JTG-\3LE^#N1]OK]2!>RHQN#X4`I
MXDIQ@(8]8=4:!NQ)CDW#5:@&;HW`'2\Y,&L]G5QY`LNNJIXKA0XBW1D2%4?P
MMQ*9>Z:67D!KJ9:NIB@>*L"I3H[%FB%:(G)/54/$$?U^F`IW$*0:G%&L_AE\
M[NFMQ!3_.?&?2H+D@I^.,`KR"W\W@NVN@-5RNO@!*;L=SU<@@9ATHW<5]D>A
M<8#_>@,RQ%/0<J&$U(.;Z_2HT"<^0>SM"@0(!6T[7>,;*.>Y"0Z*@>&+'W+7
MAWX`04'\!1TD@-5DK+A(E3S['*:+8C=.4;EV#NTZU);VE-/)V(%3;Q"7<]_B
M]C3VSGIHN_X'O*I<61U+N8[)*QD'[9&EUO#4DQJ:6RJADJ;>V`@E%V)KV%3+
MK-F6`J%$F*:7%"&5<I@SL[X>II)*JCRHJ"O.7)=3[Z7JEIUTJP&7;A.M_:)Z
M@EP:YZY$NW7"<]<@QO`(U#HT7BHQ>\.KW#T+_66K$HPASKA1;G-QY4<CAIR*
M]`*YOD#"+S`UMHDAQH=V,3<D,C?H2)=XX(._I0@>JOG8D7PG+H),XV+H;*#I
M405BSZ9`&U&<PN%:"QKM>,_7AF9'&X;.U"4?\?UV)$B+X?JW9-K9Z]$4I"U4
MQE%\+P0[4\XIYAA5UWD,=7J+*?5UR$'Z.*5249L5J*C(%Y.EAEY'98QRPMV/
M@+U%KS;PU!KXF!F]LTS9\\31J7,<#XG3?%AJI!N$9_]R>@V+=,1B:K&8>G<H
MA8;B8B(VB7<S[*PH)SG'AD2)3@Q7JC]4M<(MER-^!6F6?'[FNL5M*@J\"]4G
MDA2APC+*D5'X>0KTS4"J<BZ%.&($"@-J"S)I@&4!!BQ/6<OY`EKEQ`620$)R
MT(`:A*W*@!(?14-F=;0/%C!"C?2SLE6EV8HG/PI9O3-`+*^GXAM9^#Y69JIJ
MMM"BG#A4DZ8;G\@5[S_7%O=OD<^-@+<6-2Q,8ZOINN+5TEPCR5+^N[:)B-L%
M/W'$9UIRJ(0@I)C[&CV6Y;ZG0V&UI$#&1HK2/2!3WZ;\R-F4\=C+4]11262]
M!(@:T@%TR+P,,UI$WEZCIP7>$V\::D.#6_.SZLYL>)U0I!I(RMB@JK:2CD[A
M?0-,3)'1)08`A4&YRD2H,@6M#F0+[0?J5%9$#U1G'Y<*\.7#LLJ&8YDMYNTF
M\VR?G7:L3+*4]#]26YC6@PQV41=HZDHAO11X1S7#(*@`F32`U%-^G7&@6J-+
M`JF[#<+YH!J(AJP<^6'W=46;WS9.7H^R:DD4IIFM$4]??"XC6<%SM+QNHC9(
M*^?)H-P_J0[LU<1[:2JU_%3UXV2^=(G0G<@)O<8<#4G#^$E1/-K5<VMHET[9
MVYGCS!:P3-[(LP:5>>9R\ZUQKR>9U7<F^_EK_HAUY22V38,U"7>FN?B#EK^A
M?+)+M]")\K)OFZHQ5>[=@2I/C]C<YH92+1])>!Q7_4W$Y"Y]F$$=P)'U$ZN=
MJ&Y-3<U'R6I!^NY"^8N7`(^:>90F*97GGY'4JF.%^%/[IK?Y._-UGR!60Z2>
MHM,9WA)%V71:#_O1N>7]JV^TW8GB/^]681&X)*)1,W(T^&Z2P@7\IZM6Q]5[
MNJ:PBUQ`__`EZ&&^B3/*C=VS/'&0:>I&'/K\V.]OY.]"EJ"$AP`)U-OEH,?>
M3^EN*.5T.>!([P#`X,?<LFD"D2-UR(RNCT?C960.=#@V2V1BL9VQ^(S?O?RE
MV!!&]5`#K/+!J!-2I;N`W>`>`:@O)P&0>^2,4RT*JU'R7;UBA;$AN,^.=)H?
M8KA.O+3E`<@OL$6@W148VP(94?C>A7R5>MLXQFRPE:TG5ESJH8QDC1LTC5SA
M+S?-24PI]Q=K]/R`<33*XD%@P@*):@'\.0CLE;YFRA#-.\7PDNK0DZ+=I]C(
M[JU3D3<`364&\7B1:@!'-,2'24SA.5;?R:6Q3J2GEH8Y+*/<CB3SZ>=$^7W4
MBYZ[YCCGA8&^U]KXWS^;-:LXT!+/2F%#3419F6=D\Q@+M4QIN>(<<"T7UQN[
MSW#%XD31+C@,PE&0\2D.5+Z?;G.!`DI)K2N8*J8*5]03@)`QS*@/3N,O\4#N
M/N&D%*H<N,S)Z[E:%_=AX]SNK!HI]"@,\7<A8F'JX<TEE&J,.;IL*BPHNJNA
M:D>>GFFAH&VCJ]Q\P5NLF;,>DDT-(=&&,':X&>L!9;5\8X']RD%C(R195/=Z
M4X_]-O'&1A*I/E,C2;`H%7_92E+&C*V5>!^XA&_%FG2VJ5#-_*?EE>#W0W?#
MUZA++%T@1Q=(EUV`Y''EW]+BF/WO)A`G5#TB-`$DWG9*/*UE.UAX]@-IKQ_Y
MR*N+./>(']8XD1%8^A=@:R8X.!D>>>MH>?6D]@?D)QY)Y$NIN2P+@E%<;XH`
MAGLP/)<](E')#HK$`\B<7:>_QH0RHM/<`GME8V0ET!M9>YI[Y8SH4`&AEK_?
M_)DB:OV]6H-@MH+)O<R]1SC>!$(%-A8BL0T*R@*2\6#T1K_!TQ1C0J5X)$1[
MC/?A*JLQT^WUHI0XZ\?[#B6YWE</&D6]8=J`'FMPNL/\)*%:*6C:L&)+M-#P
M:"1^*QNRR8I\M"*!%1EB"RG"#9?S32;I`NF@.Q#YWW(!6R"-0CNX%<BBBBB2
MB2(_(+)Z]V\,3H\@;>I3.3'Z*Q9OIEH0;$+)H\W_D6I146RVV3S51NNUPXG[
MX.9XTIJ2W;5_4EXM.Q'#,/!7>@P20BS;!I;CBK^`2P@!*JB*D@*_C^VQDW81
M!TZ[25/7KWAFQ-]AX^\@R2^)JH4*#%;\/8I[S?HT:ZD&E:-[C,&#F^-;1^0_
MFC$]-3;S\,/>_L3O!WXX13JA!G?[]\Q[<.'AC*JY.Q`W=9+?P;VN[5/.8AK5
MK/JF\[DZU848DQVQ9\2B-2LR-UN`+7\-8086.B)>=B)>AI5X(9M=*"H[R*VH
MH2XU<R??.;*=O?O<[.*KVO%;X.,T/&*((AG$J7J14N3E%@4SPNQ105\U0+_2
M`+UTO'>_4.P[Y&Q[Q(K+UO01T*40I\`)+,W6!GT%28/1M$9><*N*L+*JN%NP
MEK`XQ5Y2+/!=8_A#8>(Z&!OS.Q6;Q22E#22O.JE32*SK4PD99^K[N#29U=2A
M2D&1HG,Q^?C2W35D)ZJ0$$S3F>M@V8PL2YCT'Q&!F!KU7/LBFXDX*OF#`YJI
M\7G3*Z"\_._Z"O%/04`$X$!1SB"U726W6-4Z\U'$=R/Q,6\LE2;?`54"C"WI
M`@%W//4.SEX7SXZP(<@IG6(N9(T;I[DNLM8ESGRID8^U[YD2-"7U6![/:BO.
M$TZ^CVG#&G>5GE_Z`Q+R#9=;40*'R6@=7@CN&7!I8NNU]FXILN5_]X<]T&J/
MY7D40^FI&H9ENQCU59RSJ^CE*@HYEI6UV[B42F*TA^5+>2$ZP`9X?O;NI*OI
MZ-5E74K*@#KFUCDH(SF%]:3&3U.G=^E^W;^4[Q(DTA;DPKMJ(^/BC[13,?T?
M]^7"@/%'@`$`<RBAD`IE;F1S=')E86T-96YD;V)J#3$Y(#`@;V)J#3P\(`TO
M5'EP92`O4&%G92`-+U!A<F5N="`R.2`P(%(@#2]297-O=7)C97,@,C`@,"!2
M(`TO0V]N=&5N=',@,C$@,"!2(`TO365D:6%";W@@6R`P(#`@-C$R(#<Y,B!=
M(`TO0W)O<$)O>"!;(#`@,"`V,3(@-SDR(%T@#2]2;W1A=&4@,"`-/CX@#65N
M9&]B:@TR,"`P(&]B:@T\/"`-+U!R;V-3970@6R`O4$1&("]497AT(%T@#2]&
M;VYT(#P\("]45#0@,S<@,"!2(#X^(`TO17AT1U-T871E(#P\("]'4S$@-3<@
M,"!2(#X^(`TO0V]L;W)3<&%C92`\/"`O0W,U(#,X(#`@4B`^/B`-/CX@#65N
M9&]B:@TR,2`P(&]B:@T\/"`O3&5N9W1H(#,U,#<@+T9I;'1E<B`O1FQA=&5$
M96-O9&4@/CX@#7-T<F5A;0T*2(F,5TN/XS82OOM7\+;2HMMCO>W<9B9!@,7N
M;(#Q+;,'6:9M9=265I2[D_SZK2=-V=V=10-NL5BL%ZL^5GW:+CYLM[E)S/:P
M2%;+36I6\,=?29Z;<ETM5ZL5[#\M/GQVA6D<<:R,:Q8??OZ:F*-;/*Z`)\_,
MMEG@5V6V+XM?HV]1\RV.']-DLUZNHR_Q8[7,HSY.TF4:F7Z,DU6TCQ\WL&?C
M)(E&4^,_%Z]@W\$G_+/Q*AJG&'G:\]'PUXD/$?<4/R+??,>:&!V()M)1GYDJ
M(FL0V=#15FR9[YMF3F;)]FGH0H5V;W:\_T><Y7<6M"KLXW$DY^Q3G!3+++(S
MJ>SQ""*]S>XB<G\#:DHA`)8&C)[B_VS_L<B6Z::L#!B15,7:;'^DX"=%BL'_
M-9IZ,YVL(:7+)#JV#C5MHK$6=S/VJXH\SW]Y?>%_+?J'-H$U"<8??I^LG&%9
MSO0'W@9=O"&BS$>\Y`S-A=5DZ#Z%I>[H<&=TS4>>K=E9E6]:5N`N,[%[7CV`
M<`X9T.2$;!E9BHMFX"5$%F,JU,;:?2N,1T?1W/Y=PI?[W$TY>0_]2.:SAYNH
M1M\KD;SA:$%8R5ZA@1HPS%F^2./T)*\[\+Q^MB1TQSO@-V0;948:/<681AR)
M#68H'K+H@`0`1)(CG#`8;7>J06HHD-G-H&+D8$NV"^U(9M[(PMAJ%E?B"672
M]W/_THE+^U"`#0.XRA,)8+%:<P#[0Q"_,F+'O\:/:P`!2S7>=78$O246@G>B
ME$VB-/V9:1.5R-/`JPY7]63WO%P&,KZP'^A`#@&:>CD">+,/Q8^&<ZR,G'!8
M425L6`>1D(XL[>J*JSL+11!0?F''*.$`+0YV',&\,$(E!HB^4DDQ"`:$-0/G
MUA#/'F-<P,5O@/2=%T:((W!`5O_"_^V!_Q$GD\:`LC=?7Y-H'/PO$*"06!.Q
M(S[^A>PDVC.?8EF&3-Q$.U[R[YE%0+'B.1;+OQ?>$3MX\8"1H;JELWMS%KO,
MP%9[,R$1JRA4)!)8CV@],C?K,X=0@D1)3.88S-QEDADNS#GTH:R;?$X5$,H-
MW]85QP((6PF""5QY',.JSB$?^)=15/8:JY@%"!,*52$QEW"XFH.=0+0B&21G
MAL*HE``DX`D`!JV\"BL/E]\5(J&<]^%1V<=Z?>4856PA=G#%SN*T]L!9<)QV
MDM56LH1J6/*<;QC+F`@=$[B2B;(DX8_ZR`%J%TFIC]PJV_A+*5E9A;;FB`!I
MD1=@X>=K_9<<H9S#ED<MO(!"P1X#,&'+1<O,YA,?O3#+'W&:"5I`6?\-'QV`
M@'_C$[1CCJX]UE>1-\((#[RPL3GQ1TWBG"7(`C9R]Z?M(EFO3+%.EZ5)-AMJ
MPI80V=$N#HM/V_N^#+DK,"CGONR-C"6'"GW8R:%,+I(=PE=`LBYTIJ(<&F9M
M@;RDC>:KL]>WGYTME$?!CR5)_DR<LWWSW;3.-/U-1E]5LWUZ6K0/_G6_]B\_
MO)<J29%P/_0MPBRF;A$S;!WYCK2,MHQ,BN'\[/@GY\!0WHY//C#XC!S@5AK;
M#L&[9.KYTV'JIK'*H'L-B;?2%LI31W>22Y#"9S%\7"!>'SDU^1T:K7W2QVHR
MM3/VN=6W397)V_-ZL[CRS4Y9^9I%""1SH&3M[[RVS84_-`!%=#6L\(8E9%@1
M&`8GS(W,VNR9("([3A:_K9I$=C^V?]J]UWEH&PX*18JS.*-(O8D8>/=B`]]Y
MEL+GCVRP[=IG.ZKRP"=)YHR3N0J3N8A4^R1M)20S]=MZ]!-WOY>9YVRJV`FP
M24!6X`U`=[\6T%POS;_:&"'!Q6O(E8J&(OSMB,J_-5'.O-''U(6F=&(9`DE>
MP?RP-B7`2?X70`(#7EX4P!T"2>+38ZV#7!V4S4\8A%)[HZD=[3OYZ7NS=]+1
MPWJQ$E@7+!70E#PC\26)AU>UDF3/H^E!P+29P_O43@*_DW5R2U!CQI]#R^OC
MO3PC`,_8/[U8W0F$#"&>CU-KG5I!KV8]?WJ8>`[%ME[6&&9&47`LTD1*<ZAI
M4L2.94T-#*)&EG&WZW"^/<%LR$P=;?,O=]26QTS\9G)+O\R^8U+`T_,XBJK,
MCA87:-A8*RWE&U7*,2(+U0:F&M9T!D[#ZO"338>))X<B%/)Y=FS'++='7N(D
MHWA?6?E7&*?`.Y9'L;EI5GR>27!'ANG"5[OS^%5?,0_3J9``C9!ES\I44VGK
M"08%Y]&S4>$$TFY03&T!S*#?4_!Q=C(P;"J*&$43A@W;BG@J)'@1%7+/<WB]
M\>.Y[2]JO,^N+`,\(+]]UNN3048R0;T^!L`VA/Y2M@.D=#J!%=$<!J>QULC5
MS5T8]Z%_KAG;74A0@50P;X2"-ULWNUL/(NE:0,1)]0]AV8W.2DWJ?W.:[=O=
MK/_31LW,(0F<M"/#AC.WQ>YQZ,W&TS\X?PUN[*S3_A'F!/9>]K7!Q'LOM6>?
M3P#Y=;0)$6:5;&0.%920.CQ067$E35<HH3KG/5I+W>WO<&8GA;^7_T?"C<M`
M`L[W`,)E'-0L<XR!&0UMAB7^C,)$`!VZ@$!FX]]`'OT$R$9KX^VO;SA9`5F-
M\,/<H?=W'KP"T7,@>C]/;_)OZOUP@('#GR^8(#Q8^+21^S\2@ZYH\?]FECY8
MC%>^3C25G,,!M>5#@XX\6C5Z&)2H\LG.TYX=TJ*`G/1U<1`5HYF7J$YM,\S.
M_(`IV$5"UER@J2`?O@-XP9-0']!QB`:U:1P0S(D5>(?7J93Z[#^M<'MQ*P2Z
M6,\YXX6@'KBE!Z.6[/F?"/`"6]8U6C=8@$%(V10G`,.XA(D*DAJ(<\\[(R*)
MRJJ=XU&AQ<$)6BO1Y6Y>M-)')[N&)\$1"M]-,`?JBR8L%`.@?IH<F_G`O:IL
M6[R1+(*'N=#OO<C!&`#QYA@6!"QWPM01DRJID;>*)C[:GYVRC\B0::2Z5AAW
M,U5=.[$TR[O.7-2G/:2,7"K;C>U"FE[=%-M%KL,50-=9]1]$/RLXS=0*L_EX
M%%&6HW&>'F;P2?E(P4^E@+',R^AW/)\2_)1"&IB$D)`SXF!_3_<K9X;1`X5N
M.=_*X2,$0PLBS*@M&(ZDS_RO)98]G]V;$W^$`IGCS%:\.2C-86E5EMKTRTOH
MIZ<\HODGO7ETGMMG+#Z$!_]:$O#0B(>N)*C?2+,5(`R>*J^`A"T7ED(9S5_+
MNV::,N"E'D?=F5@%]B4`,E.MD#2'(#[GL?**DVS''5HFQ6M3@30&(DTBPHIP
M'GUOT-')*JUTT*EE3MKS/\)OFB+E92]9'7L"$,%=_XFWJ!G`M;".<!,V>`*P
M'VBZWK6BY'CM.\J@32O#-JVDH%^;&.P!'N&I?1IXU>%*&S\P>#>STDN_:<YR
M[KS99VI@"PIT$@R+&QP6[U.TND;/IVCE4[21N10OYF>XB@B:\Y'1@M](^CB:
M?]8O2U1;OC^)^@M*RW`2+2/O%H7W[7'WU?N1&/$5$J69!WL:+R&+QE;OS=1-
MTX]"U3MKK'EI-=S!K7;UB\-[_LQ95)/$KH4)0PZV=(-Z/9""=+/RQ$/1PG"R
MDT\;O-H5)0+>&"2+,]@6L/2$[:W(^$2KM5*J>3GQ1R\C3T:]`/6GN]E!(@TA
M:02K69%5:<2DCE=2S$I7JK3!5)N%V@U)R^3^$.9F4J0W#09$+EG+M),$H9-'
M%(/W2+5_YZH3_35628J'S=S%W4S._'0K9X2*R06ANLPNIR>B^CS)">^U$^X&
MNPHR4H^,[LY8]<*Y]BA;E#@4(ULW(M6(:H[&J#KU*D^S^_I?W]6NW#8,!/M\
M!4JD\8Q$PJ);9]*Y3*I4,`UID*&&&H*T_R-?G'N"`"F[DHC'X7#8V]LC\7I/
M[1[:)\?1!?RW6+"?.8>6BE1%`^\8?\>R7S=MAD6KV)Z7W#OI_(='IIRGZ(<M
MK?_%^T/5TAJGXY\V>5RD-OV:(ERU=3\LY6HXO=`4N1/8GAV3=I#]VD)R][4K
MB0?[KCXL96P^[P^"4%%=S6>FN*)##1K^F>LY)I(2S)%PT199TB*0:5DM!F1S
M8?4K!/RC2``_FC0.H<K7MMLJE4!(=JPW`(LY6$UN4[Q\TRD`ZC?^C+PCW?AS
MX9]9[#`T&O():.0C!+$BEX`9(SL]+8&&(3`U=D(2+I]8V3)^DN\(55BJ*8IQ
MGRU/^1#UW8`PCI=B==RY4Q==C-,??6#'#PP/D2@HZI(CEQH+[Q?$$`RI@XX=
ME'BZO`=9!1B2BQ(,$UP"O33P`$8`VSLH);I/9L2'^[9E#31$?2S'H_YY&5.1
M-H?3J1`40IR@*\(0\A5_<+OBZ8HK2!V__)/U1CW4F]SXMXY9DD]=/&,)BY`J
MDTS`D0]RI/G-[HBA?(NW,MH<(79KXT`Y5>W1V!.BG"T>ZYEON53SO`E@--:,
MK.ES[(215S!_UZ)Y$)PBU5(HG2V49F-[V7)_!S/4!811PCCI)D$\IT>D$"JT
M%=';;.JCC@#G9+COO*BS*2?_@WAN2,0U5I9OM6DC`7D\%G!JJ0`?"W77B;J[
M>@JP*+E7GH++\S<3/@STBVSB=.U*(NYL2;V=5?LH"Z#*33?^AC!`$!#+IU58
M=5;M\;O!4>;L^Q2O<5@U/;21UPB5?=3S($%A9D</1*.21NRZ4]>=NNZPV,F0
MXI^S1SQU@M:)WE1A"5I9$O-"9+%&$O,GR2K4R!4/F7`^(X-#??8I9Z<9IWA1
M'O`#BXR?O[[]!U3/C)L*96YD<W1R96%M#65N9&]B:@TR,B`P(&]B:@T\/"`-
M+U1Y<&4@+U!A9V4@#2]087)E;G0@,CD@,"!2(`TO4F5S;W5R8V5S(#(S(#`@
M4B`-+T-O;G1E;G1S(#(T(#`@4B`-+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@
M72`-+T-R;W!";W@@6R`P(#`@-C$R(#<Y,B!=(`TO4F]T871E(#`@#3X^(`UE
M;F1O8FH-,C,@,"!O8FH-/#P@#2]0<F]C4V5T(%L@+U!$1B`O5&5X="!=(`TO
M1F]N="`\/"`O5%0R(#,U(#`@4B`O5%0T(#,W(#`@4B`^/B`-+T5X=$=3=&%T
M92`\/"`O1U,Q(#4W(#`@4B`^/B`-+T-O;&]R4W!A8V4@/#P@+T-S-2`S."`P
M(%(@/CX@#3X^(`UE;F1O8FH-,C0@,"!O8FH-/#P@+TQE;F=T:"`R-S8R("]&
M:6QT97(@+T9L871E1&5C;V1E(#X^(`US=')E86T-"DB)M%?;;MM($GW75_3;
MD@M+4?.NO-D>9R:+7`:QL/.0+!8,U9((2*2'I"_YC?GBK:I335'..L@^K`V(
M?:FJ/MU=E]-7Z]FK]3HQUJRW,[M<K"*SI'^T;)*8K,@7R^62YH^S5]=]:JI>
M)):FKV:O?KVU9M?/YLO%TJ9F7<VHL<P*LWZ<?0Z^!.'<VD4>;,)YM%RDP9>0
M&C:.J'D;SHM%'+A#2$O9X.`Z$UH;O.5N'#3A?$5"&W<,DT7FNS5DMR$MEP=U
M10HD6PYU&UJVJ6*+<)XMBD#L&;].R&;]8FQ@%;@.BYERIRWG>K:9!F9H1;WV
M0/!Q6/$'H+Z%4<SZ)23/U<7D'FV"3+^'C;D*YSE)WDM?U8&VF\J7&`).`#AX
MM'W(AVNVF.R`I(60V"@5Q[?P7^M_S.)%M,IR,[<+FZ=T5;_(]2V3"/>7+*,4
M]P>U'/!SVM3A8*I#61_["S[B56!TAL'9X%CN7&^>*QWJ\BN:]:$>:I;HZKY6
MJ9W9=NT1MX1]T_60,_R-=V:#WK`'!6J@TWLKJ[T:E]EVBV\]]+*_]=_%"U/9
MCVS-;Z@+L0J?Q=VTTX=L#NV&5XF#(62_*64([5I^6S[E/&B@8B#0;%Y-)V':
M5*'>-(\]X*-KJ!H,JZDI"$S0E18G"["*F;W90W"Z"P!4_`LYB[F_[&@1IS8;
M+SLNQF!-?;`ZA.>*C8A76O)*.N<8;DG0NK\DH&EK$J<:<3'N&D&6BG,6?J;>
MUA4'J'8E-$G=_'?[HM]Q/%(D<@S6/[&`*JOCC;)FCR\'6DZ!IJ/B*>)N5LT=
M)/?,?:C%XLT$`\M0D*D3LJ/^3/S8(BK.XT<0QL%WH?'_BR<YWA3'.ZZ/Z/*A
M95X,*HJG0=NN[GQ(P6U6H]MD&E+NCD43V,D"U[L&`\-X[XEDJ,P?0(*])(%Y
M++O.C\E6>C>8;=MA>1*H==+XD;HWE[2W8$>WFM'B4B`(IS?RHM>S@V^_A(;O
MLEA&BRAX`R>`?^AMFU]P$:.?JI]+=J=^Y_Z$CZCCULBUG5/WNE"][QVL]\Y%
M=[ZM#U[!E.9'.,QC/:BB\0UGKA$\T(`"?A5.WX\!]UU4T/HO./'G@'#Y`]_U
M?J\)]IK`>.'WFJ@#)?"N['1%SI3J$OHY4`I0V8.C*Z[48`?W[=Q.!P[ET';>
M'#F_8JE8ZO[,9"O7_]PY]&0B%/@B:/MQ.]Z+/P>C=XLS#:/_]65U\M<7W4@"
MO3@5%CLR';[#'2JPTAQVS`]R1RW&AS"G.ZWEEVN#E;QM)?]3;C3DVL1C*%F)
M!'Y-\U/*%X:E5E(._,R?]U,)Z*MT&'$&@)DVC(2J8`HJ#1QIJB.5CF8V1A4P
MN8<"UATM*DNQ,9VE?NX;8DK%"![6IIM2+<5AS@R[,.+<==]LSI:#Z!Y@8=&?
MW0\2-:<NO3^K6>RK(X.4^@2BE#5)D8](G!W9S`4EEU^10$?E=HQN1:?*3DF@
M[(H/!G.E&#Y`ZR!:%#@LH$MN)AW,*XB'R43'0[EV-L+IOGX+8\L.(B01RS2B
MLE'T+6`!O8<%$XUNPY"5).*$\\;Q/!F'P)-8(OZ1B_M.#3437$_>SJ:$N@?U
MO^Q*=18@[#=JJ1*1_5GY\25V:?,5+J[7$C<6+ZV#G"#(1>O*F;8S[5C/4`)-
MU1Z/JJD*-0[M1%;XR%1+<C:9X>\=AN[/BN?==-&>LA4EF4OP^IV,<:%R:G8X
MX[1`A*&A<^5`Z?5LR[FON'FBK*+76'?;+1TFE=QJ""6=/3B>(!=L.YE@"D0#
M$3FAC#_4S4YUO^J,XPTD@2HV.FIVS!$*'`KI/9]^#&U"7V_>-4Q<U)Y('NH'
M6'!`XOS\A:D!^@<:.N(%S)T:Z1EK%+0-US"M/.R[%R`[NK.V.ZW1/P,^3-\'
MR>J4QB--`^2*$5<4R44).2MEND1R8B0Y)PHHBQ4<\#R^!^4A1AX8R#Q![PZR
M&.M#,*"(9XQDPU225<2$G5/#"IGL?"%=FT4J&<8DI^[([]5RW/$H13'G6(/>
M5@P,;'AJT3#0/1!B7)>%UC&,$GU*T,R^5/"`_=5-,#2P83;HWK6`"F,,F!?"
MW$9%'[FR%>.DHE!$((Y3M[?)B6CFN!NA29'$RT@@T7GR-9LH$T4M""*%:J^<
MH?)LLIF2!\X-O0%]5,%^H!#O6T]L8-V<""U8Q7/>LRVKOH8=XG6F_9Z5]*6R
M5!A4\*7T1O;43A3NIA(=LZ3SG)"-.2$><\*V/1S:Q_ZU2"Z5L^2G!]^81S+-
M(V\1&UMD``;`K%5`9L)97X?S-,XYT-]36NKJ\F#6>@DXT@C),Y(3)4]N=X14
M*'#BK:M`)4;!JE:+8K6TTZI\VA.*LN9V:[/,FELN;:N@,?^LI?Y4TG481/H=
M9`)#YDIBE[C"83+Z@#&8ZH0B;"[,[3U,GNGGR_PL2Z0G7/JL>Z>)AC[L\X&Y
M;)CXB8%"JEVF;9Z]D+,QU^5DMI9?+JX%S'32;#`.26-6G*.F6.(3\;1*/"^'
M,),3R'`<S#9?2\=\:H4=";6QLH)5.?-^8:ZFPZK8TU"L,IBN8??"7-]\-*4,
M$0'\'5H0@1($-["#"35ZEG/3Z)1S4XUK3C1I\/1:[)C8+N=,`-(@R6-MQ3;'
MG<R][Y!SV^+DW$D\!L3)M]FSK?CU%1>(#%%>(.(DD03BXE&>$G1YL=&].?,[
M6A1\P<X9"R4S/AL*_P:59X7E[#H6]T)W>_YPR-7'O?]\"6IY(<091_XUP+6*
M;K0S9].NNT.?T71#O^#4!I[$/Q*.DD$5%P^^C$VFCZ4>`%@DIO@PC'O23J58
M!CSU:/=UXX]!&T*KCFWGB$K]%/(+O%F-*ZO]#\BY3:-G5]F")VT1ZD8J^2IX
MI#U'S/KKRK>HF/%<'GC6IJ)4";0U4BYTD8A/?7?DU`6R`HN#+LXI7T:4K7G3
MGBAJEV@7T3A^T.R8.44(@C,L8)ET&-87$JD^8GSP=IC?0-V\O'M/6EFL$EC[
MY[!W?F>#GW*=-]'[H<EBE=^'<-9&!?I0GI]^K6&$Z\Z+4CI>G+*I5F@7N4J)
MAA`ZU$49IK+HQ+,XCP[=O33$6^DK;I1HR3B/IVR,^W0L:L58U#AV/X`D_8'>
M^@/"Y.96+-^:/W[3@4]T3L'-1_3>7/`W\=QJD`<H5>;[1FZ5N(SKQ%X/#R<N
MPV'6N`V1)>8^R@(S)B2B@%XEO_<Z-HB6P^XV!MV]3L*DVE<<ET#'%88^'6PZ
MH9'DLLV@8J6GR!/5=BMXGRVBV]J49U!490L('?8S>#)Q'J2G=]@R\^\P-_`3
MR;^S3*F^W3XX7"'!M456\!4F.>=^STM.1"^#J8^<X[;;NF+"<0O"48-Z[91;
ME4/;>>)$B?EV2@W!7'C)F_4L*@H3Q<EBE1E+;\W(D$1A.C?;SJ[6LU?K=62H
MD&YGO'>:I'^T1(^3B5T1OB.J[UBZELJZWE^N;SZ]E=?M)0.TP3NSOKG^[</'
M=Q]_Q?C-[85!Z\,U#H(63;`H2%JT\O5AF9Z6B/0PKN1%4@2OY5K,OW_ZS]"?
M/X4T+A;+PMB"#DPW>'8.SW<?1X0PIXM*J-;2[E\@D$H&Z^'@7DO5)#:!UV1?
M;\#[G/*_07(`'@3R,5SV_C,-:"LR,S5-P15B6`54'Z0*`FH$=FH5_$'EL@4X
M30"S(+X"`:,A`*W6,R'Y(AU:1\'3CQ$X_>!K'R`E)$,34U`P6@#C`RG\`/,=
MMOX*96YD<W1R96%M#65N9&]B:@TR-2`P(&]B:@T\/"`-+U1Y<&4@+U!A9V4@
M#2]087)E;G0@,CD@,"!2(`TO4F5S;W5R8V5S(#(V(#`@4B`-+T-O;G1E;G1S
M(#(W(#`@4B`-+TUE9&EA0F]X(%L@,"`P(#8Q,B`W.3(@72`-+T-R;W!";W@@
M6R`P(#`@-C$R(#<Y,B!=(`TO4F]T871E(#`@#3X^(`UE;F1O8FH-,C8@,"!O
M8FH-/#P@#2]0<F]C4V5T(%L@+U!$1B`O5&5X="!=(`TO1F]N="`\/"`O5%0T
M(#,W(#`@4B`^/B`-+T5X=$=3=&%T92`\/"`O1U,Q(#4W(#`@4B`^/B`-+T-O
M;&]R4W!A8V4@/#P@+T-S-2`S."`P(%(@/CX@#3X^(`UE;F1O8FH-,C<@,"!O
M8FH-/#P@+TQE;F=T:"`R,#@@+T9I;'1E<B`O1FQA=&5$96-O9&4@/CX@#7-T
M<F5A;0T*2(FLCS%K`S$,A7?]"HTR]'2R[)SMCE="H&NUE0[E2#*$$GHNE/S[
MVCDZ=:TT2.CIP?=F@]$LHD<[@1<NBM)ZVS1GG$KA'*7I'S`^U1TN]?XA6!<8
M#R\>SQ6$132A+2!HW_!*\\T%8:5'M^-,^)_EWNP9]@9!`L?.E]E/J%XYHO3+
M>H03S/8G3="(4TX-=4LS=.HXW:G;EL*&?G!#XD2K&SP'.IZOZ\VI<B&<NU+H
MW35GH/7K<GWHET"X=T-A3[4KGCZ;M4_^1?T18``M?$57"F5N9'-T<F5A;0UE
M;F1O8FH-,C@@,"!O8FH-/#P@#2]0<F]D=6-E<B`H06-R;V)A="!$:7-T:6QL
M97(@-"XP-2!F;W(@5VEN9&]W<RD-+TUO9$1A=&4@*$0Z,C`P,C`X,3,Q,34Y
M,#4M,#<G,#`G*0TO075T:&]R("A'<F5G;W)Y($)A<G1K;RD-+T-R96%T:6]N
M1&%T92`H1#HR,#`R,#@Q,S$Q-3@T-BD-+T-R96%T;W(@*$UI8W)O<V]F="!7
M;W)D(#@N,"D-/CX@#65N9&]B:@TR.2`P(&]B:@T\/"`-+U1Y<&4@+U!A9V5S
M(`TO2VED<R!;(#,R(#`@4B`Q(#`@4B`T(#`@4B`W(#`@4B`Q,"`P(%(@,3,@
M,"!2(#$V(#`@4B`Q.2`P(%(@,C(@,"!2(#(U(#`@4B`-72`-+T-O=6YT(#$P
M(`T^/B`-96YD;V)J#7AR968-,"`S,"`-,#`P,#`P,#`P,"`V-34S-2!F#0HP
M,#`P,#`X.#,R(#`P,#`P(&X-"C`P,#`P,#@Y.#,@,#`P,#`@;@T*,#`P,#`P
M.3$R.2`P,#`P,"!N#0HP,#`P,#$R-S$U(#`P,#`P(&X-"C`P,#`P,3(X-C8@
M,#`P,#`@;@T*,#`P,#`Q,S`P,"`P,#`P,"!N#0HP,#`P,#$W,3<T(#`P,#`P
M(&X-"C`P,#`P,3<S,C4@,#`P,#`@;@T*,#`P,#`Q-S0U.2`P,#`P,"!N#0HP
M,#`P,#$W-S(Y(#`P,#`P(&X-"C`P,#`P,3<X.#,@,#`P,#`@;@T*,#`P,#`Q
M.#`Q."`P,#`P,"!N#0HP,#`P,#(R-#8T(#`P,#`P(&X-"C`P,#`P,C(V,3@@
M,#`P,#`@;@T*,#`P,#`R,C<U,R`P,#`P,"!N#0HP,#`P,#(W,#(T(#`P,#`P
M(&X-"C`P,#`P,C<Q-S@@,#`P,#`@;@T*,#`P,#`R-S,Q,R`P,#`P,"!N#0HP
M,#`P,#,P-S8V(#`P,#`P(&X-"C`P,#`P,S`Y,C`@,#`P,#`@;@T*,#`P,#`S
M,3`U-2`P,#`P,"!N#0HP,#`P,#,T-C,W(#`P,#`P(&X-"C`P,#`P,S0W.3$@
M,#`P,#`@;@T*,#`P,#`S-#DS."`P,#`P,"!N#0HP,#`P,#,W-S<U(#`P,#`P
M(&X-"C`P,#`P,S<Y,CD@,#`P,#`@;@T*,#`P,#`S.#`V-"`P,#`P,"!N#0HP
M,#`P,#,X,S0V(#`P,#`P(&X-"C`P,#`P,S@U-#`@,#`P,#`@;@T*=')A:6QE
M<@T\/`TO4VEZ92`S,`TO241;/&-A8V,V.39B8V(Y,C@W8C0U,V,V,S0V,S<V
M9#1D-#%C/CQC86-C-CDV8F-B.3(X-V(T-3-C-C,T-C,W-F0T9#0Q8SY=#3X^
5#7-T87)T>')E9@TQ-S,-)25%3T8-
`
end

</PDF>Exhibit

10.1

 

COLLABORATION

AGREEMENT

 

This Agreement is entered into as of April 19, 2002, by and between:

 

•                                         SEATTLE

GENETICS, INC., a Delaware corporation, having its principal place

of business at 21823 30th Drive S.E., Bothell, Washington 98021

 

(hereinafter referred to as “SGI”)

 

and:

 

•                                         GENENTECH

INC., a Delaware corporation, having its principal place of business

at 1 DNA Way, South San Francisco, California.

 

(hereinafter referred to as “GNE”).

 

WITNESSETH

 

WHEREAS, SGI owns or controls intellectual

property rights relating to certain drug conjugation and linker technology;

 

WHEREAS, GNE is currently conducting

research and development programs aimed at the discovery of antigens and the

development of antibodies targeting those antigens;

 

WHEREAS, GNE wishes to acquire from SGI

exclusive options to worldwide exclusive licenses under SGI’s patent rights and

know-how related to SGI’s drug conjugation and linker technology;

 

WHEREAS, SGI wishes to grant to GNE such

exclusive options to such exclusive licenses in order to allow GNE to evaluate

SGI’s drug conjugation and linker technology for use with certain of GNE’s

antigens and antibodies, and

 

WHEREAS, SGI wishes to grant to GNE such

exclusive licenses, subject to the terms of and conditioned upon this

Agreement.

 

NOW, THEREFORE, in consideration of the

mutual covenants and obligations set forth herein, the Parties hereto,

intending to be legally bound, agree as follows:

 

ARTICLE I - DEFINITIONS AND

INTERPRETATION

 

1.1.          Definitions:  For the purposes of this Agreement the

following words and phrases shall have the following meanings:

 

“AAA” has the meaning set forth in Section

20.3.4.

 

 

“ADC” or “[***]” means any [***]  Antibody that incorporates or uses Drug

Conjugation Technology.

 

“ADC Access Fee” has the meaning set forth

in Section 7.1.1 hereof.

 

“Additional ADC Access Fee” has the meaning

set forth in Section 7.1.2 hereof.

 

“Additional Research Program Renewal Term”

has the meaning set forth in Section 3.3.

 

“Affiliate” of a Party, means any corporation

or other business entity that, directly or indirectly, through one or more

intermediaries, controls, is controlled by, or is under common control with a

Party.  As used herein, the term

“control” will mean the direct or indirect ownership of [***]  or more of the

stock having the right to vote for directors thereof or the ability to

otherwise control the management thereof.

 

“Agreement” means this agreement, all

amendments and supplements to this Agreement and all schedules to this

Agreement, including the following:

 

	

  Schedule A

  - Research Plan and Budget;

  
	

  Schedule B

  - Licensed Patents;

  
	

  Schedule C

  - Research Antigens; and

  
	

  Schedule D

  - SGI In-Licenses

  

 

“Antibody” or “Antibodies” means any

antibody, [***], with a unique

amino acid sequence that binds to a Research Antigen or Exclusive Antigen.

 

“Antigen” means any [***] binds.

 

“[***]”

means any molecule, including without limitation, any [***], that [***].

 

“[***]”

means the SGI Technology licensed to SGI under the [***] (as defined in the

definition of “SGI In-Licenses”).

 

“Breaching Party” has the meaning set forth

in Section 14.4.

 

“Calendar Quarter” means any of the

three-month periods beginning January 1, April 1, July 1 and

October 1 in any year.

 

“Change in Control” has the meaning set

forth in Article 17.

 

“Confidential Information” has the meaning

set forth in Section 9.1.

 

“[***]”

or “[***]” means any [***] that

does not [***] or [***].

 

“Designation Renewal Fees” has the meaning

set forth in Section 7.1.2.

 

2

 

“Drug Conjugate Materials” means research

grade cytotoxic compounds, including [***],

and linkers for attaching such cytotoxic compounds to [***].

 

“Drug Conjugation Technology” means drug

conjugation chemistry owned or controlled by SGI, including [***] and

derivatives thereof, [***] analogues developed by SGI, [***] and linker

technology for attaching Drug Conjugate Materials to [***] that is the subject

matter of the Licensed Patents and SGI

Know-How.

 

“Effective Date” means the date of this

Agreement.

 

“Events of Force Majeure” has the meaning

set forth in Article 16.

 

“Exclusive Antigen” has the meaning set

forth in Section 4.3.1.

 

“Exclusive License” has the meaning set

forth in Section 4.3.1.

 

“Existing Third Party Royalties” has the

meaning set forth in Section 7.4.1.

 

“Field” means [***]; provided that

with respect to use of the [***], the [***];

and provided, further, that [***].

 

“First Commercial Sale” means, in each

country of the Territory, the first commercial sale of a Licensed Product by

GNE, its Affiliates or Sublicensees to a Third-Party following, if required by

law, Regulatory Approval and, when Regulatory Approval is not required by law,

the first commercial sale in that country, in each case for use or consumption of

such Licensed Product in such country by the general public; for avoidance of

doubt, First Commercial Sale of a given Licensed Product cannot occur more than

once in any particular country of the Territory.

 

“First Research Program Renewal Term”  has

the meaning set forth in Section 3.3

 

“GNE Patents” has the meaning set forth in

Section 10.3.2.

 

“Improvements” means all patentable or

non-patentable inventions, discoveries, or other know-how developed solely or

jointly by employees of, or others acting on behalf of, SGI or GNE (including

any SGI FTEs funded by GNE pursuant to this Agreement) which (i) utilize,

incorporate, derive from or are based on the Drug Conjugation Technology, (ii)

add to the knowledge of the Drug Conjugation Technology and (iii) help mastering

or enhancing processes for formulating or using the Drug Conjugation Technology

in combination with [***].  By way of clarification, the Parties agree

that discoveries, inventions, developments and know-how made or developed

solely by GNE that are not specifically related to Drug Conjugation Technology

shall not be deemed “Improvements” hereunder.

 

“IND” means an Investigational New Drug

Application filed or to be filed with the United States Food and Drug

Administration and any successor agency or authority thereto (“FDA”).

 

3

 

“Indemnitee” has the meaning set forth in

Section 15.2.

 

“Indemnitor” has the meaning set forth in

Section 15.2

 

“Initial Research Program Term” has the

meaning set forth in Section 3.3.

 

“Initiation”  means, with respect to a

human clinical trial, the dosing of the first patient with a Licensed Product

pursuant to a clinical protocol of the specified clinical trial.

 

“Joint Patents” has the meaning set forth in

Section 10.2.2.

 

“Liabilities”  has the meaning set forth in

Section 15.1.1.

 

“Licensed Patents” means:

 

(i)            any

[***] patents and patent applications listed in Schedule B to this

Agreement, which shall be amended from time to time to reflect any additions to

the Licensed Patents;

 

(ii)           any

patents and patent applications covering Improvements, and covering [***] to the

extent [***];

 

(iii)          any

[***] patents issued from any patent applications referred to above and any

[***] patents issued from a patent application filed in any country in the

Territory which corresponds to a patent or patent application identified above;

 

(iv)          any

reissues, reexaminations, confirmations, renewals, registrations,

substitutions, extensions, counterparts, divisions or continuations issued, assigned

or licensed to SGI of or relating to the patents or patent applications

identified above; and

 

(v)           [***].

 

“Licensed Product” means any and all

products where the manufacture, use, sale, offer for sale or import of such

products 1) would have infringed a Valid Patent Claim if not for the licenses

granted in this Agreement and/or 2) otherwise relies on or incorporates Drug

Conjugation Technology, SGI Know-How, Improvements or [***] provided to GNE by SGI hereunder.

 

“Net Sales” means, as to each calendar

quarter, the gross invoiced sales prices charged for all Licensed Products sold

by or for GNE, its Affiliates and sublicensees to independent Third Parties

during such quarter, after deduction (if not already deducted in the amount

invoiced) of the following items paid by GNE, its Affiliates and sublicensees

during such calendar quarter with respect to sales of Licensed Products

regardless of the calendar quarter in which such sales were made, provided and

to the extent that such items are incurred or allowed and do not exceed

reasonable and customary amounts in the market in which such sales occurred:

 

4

 

(a)           trade,

quantity and/or cash discounts, allowances or rebates actually taken and

allowed, including without limitation promotional or similar discounts or

rebates and discounts or rebates to governmental or managed care organizations;

 

(b)           credits

or allowances given or made for rejection, defects, recall or return, rebates,

retroactive price reductions of or uncollectable amounts on previously sold

Licensed Products;

 

(c)           any tax, tariff, duty or government

charge (including any tax such as a sales, value added, excise or similar tax

or government charge other than an income tax) levied on the sale, transportation

or delivery of a Licensed Product and borne by the seller thereof without

reimbursement from any third party; and

 

(d)           any

charges for freight, postage, shipping or transportation or similar charges

from the seller, or for insurance borne by the seller.

 

All of the foregoing deductions from the gross

invoiced sales prices of Licensed Product shall be determined in accordance

with GAAP.  In the event that GNE, its

Affiliates or sublicensees make any adjustments to such deductions after the

associated Net Sales have been reported pursuant to this Agreement, the

adjustments shall be reported and reconciled with the next report and payment

of any royalties due.

 

“[***]” means any [***], or other [***]

pursuant to  [***] and before expiration or termination of the Research

Program Term which (i) [***], (ii) [***] and (iii) [***].

 

“Notice of Dispute”

has the meaning set forth in Section 20.3.1.

 

“Option” means, with respect to each

Research Antigen, the exclusive option granted by SGI to GNE pursuant to the

provisions of Section 4.2 hereof to obtain an Exclusive License under

Section 4.3 hereof.

 

“Option Exercise Fee” has the meaning set

forth in Section 7.2.1.

 

“Option Period” means, with respect to each

Research Antigen, the period commencing on the date [***] and continuing until

[***], subject to Section 7.1.3, unless terminated earlier pursuant to the

provisions of Article 14 herein.

 

“Parties” means GNE and SGI, and “Party”

means either of them.

 

“Phase II Clinical Trial” means a controlled

dose clinical trial prospectively designed to evaluate the efficacy and safety

of a candidate drug in the targeted patient population and to define the

optimal dosing regimen.

 

“Phase III Clinical Trial” means a

controlled, and usually multi-center, clinical trial, involving patients with

the disease or condition of interest to obtain sufficient efficacy and safety

data to support regulatory submissions and labeling of a candidate drug.

 

5

 

“PPC Approval” means GNE’s internal approval

of a drug candidate to enter Genentech’s product pipeline or an equivalent

approval by an Affiliate or Sublicensee, which in any event shall occur prior

to filing an IND.

 

“Program

Inventions” has the meaning set forth in Section 10.1.1.

 

“Publication” has the meaning set forth in

Section 9.5.

 

“Regulatory Approval”

means final regulatory approval (including, where applicable, pricing approval

in the event that actual sales do not take place before such approval) required

to market a Licensed Product for a disease or condition in accordance with the

applicable laws and regulations of a given country.  In the United States, its territories and possessions, Regulatory

Approval means approval of a Biologics License Application (“BLA”) or

its equivalent by the FDA.

 

“Reports”  has the meaning set forth in

Section 8.1.1.

 

“Research Antigen”  means any Antigen that is

designated a “Research Antigen” under this Agreement pursuant to Section

2.1.

 

“Research Fees” has the meaning set forth in

Section 7.1.3.

 

“[***]” has the meaning set forth in Section

7.1.4.

 

“[***]” has the meaning set forth in Section

7.1.4.

 

“Research Plan and Budget” means the plan

and budget for the Research Program agreed upon by the Parties and attached

hereto as Schedule A.

 

“Research Program” means the research

program conducted pursuant to Article 3.

 

“Research Program Fees” has the meaning set

forth in Section 7.1.4.

 

“Research Program Term” means the term of

the Research Program set forth in Section 3.3.

 

“Royalty Term” means, on a Licensed

Product-by-Licensed Product and country-by-country basis, the period of time

equal to the longer of: (a) [***] from the date of First Commercial Sale

of the Licensed Product in such country; or (b) the term for which a Valid

Patent Claim would be infringed by the sale of the Licensed Product in such

country if not for the licenses granted hereunder.

 

“[***]”

shall have the meaning set forth in Section 3.6.

 

“[***]”

shall have the meaning set forth in Section 3.6.

 

6

 

“SGI In-Licenses” means the following

agreements between SGI and the indicated Third Parties: (a) the [***] Agreement

between [***] and SGI dated [***], as amended (the “[***]”); (b) the License

Agreement between [***] and SGI dated [***], as amended (the “[***]”); (c) the [***] Agreement between [***] and SGI dated [***]

(the “[***]”); and (d) any other license agreement provided to GNE by SGI

between SGI and a Third-Party covering [***] to the extent such [***] are

[***].

 

“SGI Know-How” means any and all technical

information, processes, formulae, data, engineering, inventions, chemical

compounds, know-how and trade secrets, in each case that is Confidential

Information according to Article 9, that relate to the Drug Conjugation Technology and which

have been, or hereafter are during the term of this Agreement, either developed

by SGI or its Affiliates, or have been acquired by SGI or its Affiliates from a

Third Party with the right to grant licenses, immunities or other rights thereon.

 

“SGI Technology” means the Licensed Patents,

the SGI Know-How, Improvements to the extent included in this Agreement

pursuant to Section 4.4.1. and [***]  to the extent [***].

 

“Sublicensees” means any person or entity

acting pursuant to a sublicense granted to it by GNE or its Affiliates under

the terms of this Agreement.

 

“Term” has the meaning set forth in Article

14.

 

“Territory” means [***].

 

“Third-Party” means any person or entity

other than GNE, SGI and their respective Affiliates.

 

“Valid Patent Claim” means a claim of an

issued and unexpired patent included in Licensed Patents (a) which has not been

held permanently revoked, unenforceable or invalid by a decision of a court or

other governmental agency of competent jurisdiction, unappealable or unappealed

within the time allowed for appeal and (b) which has not been admitted to be

invalid or unenforceable through reissue or disclaimer or otherwise.  Notwithstanding the foregoing, for the

purposes of royalty calculations due SGI under this Agreement, Valid Patent

Claim shall not include any claim of a Licensed Patent that lists an inventor

who was an employee or consultant of GNE at the time of the invention.

 

1.2.          Certain Rules of Interpretation in this Agreement and

the Schedules.

 

1.2.1        Unless

otherwise specified, all references to monetary amounts are to United States of

America currency (U.S. Dollars);

 

1.2.2        The

preamble to this Agreement and the descriptive headings of Articles and

Sections are inserted solely for convenience of reference and are not intended

as complete or accurate descriptions of the content of this Agreement or of

such Articles or Sections;

 

7

 

1.2.3        The

use of words in the singular or plural, or with a particular gender, shall not

limit the scope or exclude the application of any provision of this Agreement

to such person or persons or circumstances as the context otherwise permits;

 

1.2.4        The

words “include” and “including” have the inclusive meaning frequently identified

with the phrases “without limitation” and “but not limited to”;

 

1.2.5        Unless

otherwise specified, time periods within or following which any payment is to

be made or act is to be done shall be calculated by excluding the day on which

the period commences and including the day on which the period ends and by

extending the period to the next business day following if the last day of the

period is not a business day in the jurisdiction of the Party to make such

payment or do such act; and

 

1.2.6        Whenever

any payment is to be made or action to be taken under this Agreement is

required to be made or taken on a day other than a business day, such payment

shall be made or action taken on the next business day following such day to

make such payment or do such act.

 

ARTICLE 2 – RESEARCH ANTIGENS

 

2.1.          Designation

of Research Antigens.

 

Subject to the provisions of this Agreement, including

the availability of the Antigen pursuant to Section 2.2., GNE may acquire

Options pursuant to Section 4.2 for Research Antigens during the Research

Program Term as follows:

 

2.1.1        Initial

Research Antigens.  Upon

payment of the ADC Access Fee set forth in Section 7.1.1., GNE will receive

credits for [***] Options for Research Antigens for evaluation in the Research

Program.  GNE may acquire such Options

in accordance with Section 2.1.3 all at once, or one by one, at any time during

the Research Program Term, subject to Section 2.1.4.

 

2.1.2        Additional

Research Antigens.  GNE

may obtain more than [***] Options for Research Antigens for evaluation in the

Research Program in accordance with Sections 2.1.3 and 2.1.4, and by

subsequently paying the Additional ADC Access Fee for [***]  as set forth in

Section 7.1.2.

 

2.1.3        Procedure for Acquiring an Option for a

Research Antigen.  GNE may

acquire an Option for an Antigen by notifying SGI of the identity of, and to

the extent available the [***]

for, the Antigen for which GNE wishes to acquire an Option and the [***] that primarily binds to such

Antigen.  Within [***] following receipt

of such GNE notice, SGI shall notify GNE whether the Option requested by GNE is

available pursuant to Section 2.2.  Upon

notice by SGI to GNE that an Option is available for such Antigen pursuant to

Section 2.2, such Antigen shall be deemed to be a “Research Antigen”

under this Agreement for the duration of the Option Period.  Schedule C to this Agreement will be

amended from time to time to list the Research Antigens (including a

description thereof) under this Agreement. 

In the event SGI 

 

8

 

notifies GNE that an Option is not available for a particular Antigen,

SGI shall include with such notification the reason why such Antigen is not

available and 1) if the request was for an Initial Research Antigen, GNE shall

not be deemed to have used a credit for such Option or 2) if the request was

for an Additional Research Antigen, no payment shall be due for such Antigen.

 

2.1.4        GNE

may not acquire any Options under this Agreement for Research Antigens

following expiration of the Initial Research Program Term or, if GNE pays the

Designation Renewal Fees set forth in Section 7.1.2, upon expiration of the

First Research Program Renewal Term.

 

2.2.          Availability

of an Antigen [***].

 

It is understood and agreed that SGI is not required

to grant an Option to an Antigen if, prior to GNE’s request for an Option for

such Antigen pursuant to Section 2.1: (i) [***].  Additionally, SGI shall not be required to [***] any [***]

pursuant to Section 3.4 if the target antigens for such [***] are unavailable pursuant to Sections 2.2(i), (ii) or

(iii).  [***].

 

ARTICLE 3 - RESEARCH PROGRAM

 

3.1.          Objective.  GNE intends to conduct a Research Program to

evaluate ADCs for commercial development under this Agreement.

 

3.2.          Conduct

of Research Program.  SGI

shall use all reasonable efforts to complete research works in accordance with

the Research Plan and Budget.  In

support of the Research Program, upon receipt of [***]  from GNE, SGI

will prepare ADCs for GNE pursuant to Section 3.4.  Any research work performed by GNE and SGI pursuant hereto shall

be performed in a good scientific manner and in compliance with all applicable

laws.

 

3.3.          Term of

the Research Program.  The

term of the Research Program shall initially be for a period of [***] from the Effective Date (the “Initial

Research Program Term”), unless terminated earlier upon termination of this

Agreement in accordance with Article 14 hereof.  Subject to payment of the Research Program Fees by GNE as set

forth in Section 7.1.3 below, the Research Program will be renewable for [***] period (the “First Research

Program Renewal Term”) upon GNE’s request by giving written notice to SGI

not less than [***] prior to the expiration of the Initial Research Program

Term.  Furthermore, subject to payment

of the Research Program Fees by GNE as set forth in Section 7.1.3 below, the

Research Program will be renewable for up to [***] additional successive [***]

periods after the expiration of the First Renewal Research Program Term (each

an “Additional Research Program Renewal Term”, and collectively with the

Initial Research Program Term and the First Research Program Renewal Term, the

“Research Program Term”) upon GNE’s request by giving written notice to

SGI not less than [***] prior to the expiration of the First Renewal Research

Program Term or any Additional Research Program Renewal Term; provided

that [***].

 

9

 

3.4.          SGI

Preparation of ADCs.

 

At the request of GNE during the Research Program

Term, SGI will prepare ADCs in accordance with the Research Plan and

Budget.  The Parties agree that any

[***] provided to SGI by GNE and any ADCs created by SGI using such [***] are

Genentech Confidential Information in accordance with Article 9.  As such, without limiting the generality of

the restrictions set forth in Article 9, SGI shall not use, or disclose or

transfer to any Third Party, such [***] or ADCs for any purpose other than as

specifically contemplated by this Agreement. 

[***].

 

EXCEPT AS MAY BE OTHERWISE PROVIDED IN ARTICLE 13, SGI

MAKES NO REPRESENTATIONS AND GRANTS NO WARRANTIES, EXPRESS OR IMPLIED, EITHER

IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, REGARDING THE ADCs

PREPARED BY SGI INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS

FOR A PARTICULAR USE OR PURPOSE.

 

3.5           SGI

Support for Research Program. 

At the request of GNE and for the consideration set forth in Section

7.1.4, during the Research Program Term, SGI will provide [***]  (or

more subject to mutual agreement of the Parties) to [***] for Genentech pursuant to Section 3.4.  GNE will give SGI at least [***] written

notice prior to the end of each [***]

during the Research Program notifying SGI of the number of [***] GNE requests and commits to pay [***] for the forthcoming [***].  In addition, GNE may send its own personnel to SGI facilities to

assist in the Research Program, at GNE’s expense, and subject to reasonable and

appropriate confidentiality restrictions.

 

3.6           [***].  At the request of GNE and for the consideration set forth in

Section 7.1.4, during the Research Program Term, SGI will  [***]  that GNE  has [***]  pursuant to  [***],

subject to [***]  upon mutual agreement of SGI and

GNE.  SGI will  [***]  approximately [***]  for

each  [***]  and  [***]  such  [***].  SGI

will not  [***]  to [***]  their  [***]  or otherwise  [***]  any  [***]  to[***]  of any  [***]  what is  [***].  Upon

[***]to  [***]  of

an  [***]  for  [***],

SGI will  [***]  a  [***]  of such  [***]  to[***]  in[***]  with  [***].  Each

[***]for an  [***]  under

this  Section 3.6 shall  [***]

after [***]  of such  [***],  and, except as expressly set forth in this Section 3.6, shall

not  [***]: (i) any [***],

(ii) any [***]  or (iii) any  [***].

 

ARTICLE

4 – OPTIONS AND LICENSES

 

4.1.          Research

License to GNE.

 

Subject to the provisions of this Agreement, SGI

hereby grants to GNE and its Affiliates, for the term of the Research Program,

an exclusive license in the Territory under the SGI Technology solely for the

purpose of conducting research and development activities on the Research

Antigens and evaluating GNE’s interest to exercise the Options.  The research license granted to GNE under

this Section 4.1 shall include, without limitation, the right to conjugate

Drug Conjugate Materials to [***] using SGI Technology solely for the purpose

of conducting the foregoing evaluation, but shall not include (i) the

right to grant sublicenses thereto to any Third-Party, (ii) the right to

initiate any human clinical trial utilizing a Licensed Product in any

 

10

 

country, or (iii) the right to make, have made, use or sell a

Licensed Product or the Drug Conjugation Technology.  Notwithstanding the foregoing, the research license granted to

GNE under this Section 4.1 shall allow GNE to send ADCs and/or, subject to

SGI’s consent (which shall not be unreasonably withheld), Drug Conjugate

Materials under a material transfer or similar collaborative agreement to a

bona fide Third Party research collaborator for pre-clinical research, provided

such Third Party collaborator is bound to obligations of confidentiality and

non-use effectively identical to those contained herein.

 

4.2.          Option

Grant.

 

4.2.1.       Grant

of the Options.  Subject to the

provisions of this Agreement, SGI hereby grants to GNE an exclusive Option for

each Research Antigen designated pursuant to Section 2.1 to obtain the

Exclusive Licenses set forth in Section 4.3.1 during the Option Period.

 

4.2.2.       Exercise

of the Options.  For each Option

granted pursuant to Section 4.2.1, at any time during the Option Period and

prior to filing of an IND for any ADC binding to the particular Research

Antigen, GNE may provide notice to SGI that it wishes to obtain the Exclusive

Licenses as set forth in Section 4.3.

 

4.3.          Exclusive License Grant to GNE.

 

4.3.1.       Grant.  At anytime during the Research Program Term,

(i) if GNE elects to exercise its option to acquire an Exclusive License with

respect to a particular Research Antigen pursuant to Section 4.2.2. and (ii) if

GNE pays the Option Exercise Fee pursuant to Section 7.2.1, then subject to the

terms and conditions of this Agreement, and commencing as of the date that SGI

has received the Option Exercise Fee from GNE, SGI is automatically deemed to

grant, and in such event hereby grants, to GNE, on a Research

Antigen-by-Research Antigen basis, a worldwide, exclusive (even as to SGI),

royalty-bearing license under the SGI Technology, with the right to sublicense

as permitted in Section 4.3.2., to discover, have discovered, develop, have

developed, make, have made, import, have imported, export, have exported, use,

offer to sell, sell and have sold Licensed Products directed toward such

Research Antigen within the Field in the Territory (an “Exclusive License”),

whereupon the Research Antigen shall thereafter be deemed to be an “Exclusive

Antigen”.  GNE may obtain an

Exclusive License for each Research Antigen pursuant to this Section 4.3.1

until the expiration of the Research Program Term.  Upon expiration of the Research Program Term, no further

Exclusive Licenses shall be granted under the terms of this Agreement, although

any existing Exclusive Licenses already granted shall continue as set forth

herein provided [***] has been [***]  which

is the [***] of the [***].

 

4.3.2.       Rights

to Sublicense.

 

(a)           If

GNE has exercised its Option for an Exclusive License for an Exclusive Antigen,

GNE shall have the right to sublicense the rights granted to GNE pursuant to

this Agreement with respect to such Exclusive Antigen to any Affiliate or any

Third-Party subject to the terms and conditions of the SGI In-Licenses attached

hereto as Schedule D; provided that GNE shall not have the right

to sublicense SGI Technology on a stand-alone basis 

 

11

 

or for conjugation with any Antibodies that bind to an antigen other

than an Exclusive Antigen, subject to the terms and conditions of this Article

4.

 

(b)           GNE

agrees to contractually obligate any Sublicensee as to the making of all

payments due to SGI by reason of completion of any milestones or Net Sales of

any Licensed Products by any such Sublicensee and its compliance with all terms

of this Agreement applicable to GNE (including all terms of this Agreement

identified as applicable to Sublicensee); and any such Sublicensee shall additionally

agree in writing (i) to keep books and records and permit SGI to review the

information concerning such books and records that GNE has in its possession in

accordance with the terms of this Agreement and (ii) to comply with all other

terms of this Agreement applicable to GNE (including all terms of this

Agreement identified as applicable to a Sublicensee).

 

(c)           GNE

shall notify SGI of each sublicense granted to Affiliates or Third-Parties and

shall provide SGI with the name and address of each Sublicensee and a

description of the rights granted and the territory covered by each

Sublicensee.

 

4.4.          Improvements

and [***].

 

4.4.1.       Improvements.  In the event that, during the Research

Program Term, SGI conceives, develops or reduces to practice an Improvement

that relates to the Drug Conjugation Technology, SGI shall promptly notify GNE

of the discovery of such Improvement. 

GNE may, at any time during the Research Program Term, elect to use the

Improvements in the Research Program pursuant to the research license granted

under Section 4.1 and in the development and commercialization of Licensed

Products as permitted in this Agreement.

 

4.4.2.       [***]. 

Subject to the [***], SGI

hereby [***] the [***] and in

the [***] any [***].  SGI shall [***] of any [***] by providing a [***] of the [***], including all

[***] applicable to [***] of the [***]. 

In SGI’s discretion, and subject to confidentiality restrictions, prior

to [***] from [***], SGI will [***]  to

[***] on the [***] and will [***] in [***].  Upon SGI [***]  of the [***] of such [***], GNE may, by

giving written notice to SGI at any time during the Research Program Term, [***] such [***] under this Agreement;

provided that GNE will, to the extent [***]  hereunder,

[***] for such [***] under any [***]. 

In the event GNE is required by the foregoing sentence to [***] for a

[***], GNE shall be permitted to [***] from [***].  For the purposes of the foregoing sentence, a [***] is a [***] to

a [***] in an [***] covering [***] that is [***], and is not a [***] that would

be [***] a certain [***] were to

[***].  [***]  shall be

amended from time to time to [***],

and the specific terms of the [***]

covering such [***] related thereto with which GNE shall [***].

 

4.5.          Compliance

with the SGI In-Licenses.

 

4.5.1.       GNE,

its Affiliates and Sublicensees agree to comply with those covenants and

conditions of the SGI In-Licenses disclosed to GNE by SGI in advance and

attached hereto in Schedule D, and any amendments thereto upon written

disclosure thereof to GNE, as if GNE were a party to the SGI In-Licenses.  The Parties agree that BMS is a Third-Party

beneficiary to

 

12

 

this Agreement to the extent SGI Technology includes technology

sublicensed under the BMS Agreement.

 

4.5.2.       SGI

will not [***]  any  [***]  to an  [***]  that  [***]  or[***]  of the  [***]  hereunder  [***].

 

ARTICLE 5 – TECHNOLOGY DISCLOSURE 

 

5.1.          Disclosure

of Drug Conjugation Technology.

 

SGI shall disclose to GNE such Drug Conjugation Technology, SGI Know-How, [***]  and

Improvements as is reasonably useful to enable GNE to use the Drug Conjugation

Technology, SGI Know-How, [***] and Improvements at GNE’s facilities on the

terms and subject to the conditions of this Agreement.  In addition, during the term of this

Agreement, SGI shall, upon GNE’s reasonable request and with adequate notice to

SGI, make available to GNE at SGI’s facilities, SGI’s personnel to provide a

reasonable amount of technical assistance and training to GNE’s personnel. GNE

shall pay [***] costs and

reasonable travel expenses (at cost) incurred by SGI in providing such

technical assistance and training in accordance with Section 7.1.4.

 

5.2.          Identification

of Technology.

 

The Parties agree that all Drug Conjugation

Technology, SGI Know-How and Drug Conjugate Materials transferred to GNE

pursuant to this Agreement shall be so transferred in the form of written

memoranda marked confidential in the case of Drug Conjugation Technology and

SGI Know-How and, in the case of Materials, by clearly marked containers. When

presented in this manner, these shall be deemed to be “Confidential

Information” in accordance with Section 9.1.  GNE will take reasonable and appropriate measures to ensure that

the confidentiality of all Drug Conjugation Technology, SGI Know-How and

Materials is preserved and that the Drug Conjugation Technology, SGI Know-How

and Materials are only used for the purposes authorized under the Agreement and

in compliance with this Agreement.

 

ARTICLE 6 - DEVELOPMENT AND

COMMERCIALIZATION; MANUFACTURING

 

6.1           Development

and Commercialization. 

GNE shall use commercially reasonable efforts to develop, commercialize

and market Licensed Products, such efforts to be consistent with the exercise

of prudent scientific and business judgment and comparable to the efforts GNE

applies to its other projects of similar potential and market size.  Without limiting the foregoing, GNE shall,

as commercially prudent, (i) conduct such preclinical and clinical trials

as are necessary or desirable to obtain any needed regulatory approvals to

develop and commercialize Licensed Products , (ii) diligently develop and

obtain other neces­sary approvals to market such Licensed Products (including,

as the case may be, pricing approval), and (iii) market such Licensed Products

in each country in which GNE has re­ceived all applicable regulatory approvals

therefor.  GNE shall comply with all

applicable good laboratory, clinical and manufacturing

 

13

 

practices in the development and commercialization of such Licensed

Products, and shall cause its Affiliates and subcontractors to do the same.

 

Except as set forth herein, as between SGI and GNE,

GNE shall be solely responsible for funding all costs of the development and

commercialization of each such Licensed Product.  GNE shall keep SGI informed in a timely manner as to the progress

of the development of Licensed Products. 

Beginning on [***] and thereafter within [***] following the end of each

[***], GNE shall provide SGI with a written report summarizing GNE’s

significant activities related to research and development of Licensed Products

and status of clinical trials and government approvals necessary for marketing

Licensed Products.  Such report shall be

deemed GNE Confidential Information pursuant to Article 9.

 

6.2           Manufacturing.  Except as otherwise set forth in this

Agreement, GNE shall be responsible for the manufacture and supply of the

Licensed Products.  Notwithstanding the

foregoing, SGI shall consider in good faith any request by GNE for supply of

GMP drug conjugate materials and shall work together with and help GNE

establish and/or procure anticipated manufacturing supplies, materials and

capacity needed for clinical and/or commercial Licensed Products.  In the event SGI agrees to supply materials,

the Parties shall negotiate in good faith a supply agreement incorporating the

agreed upon prices, the agreed upon notification requirements and such other

customary terms as may be appropriate.

 

ARTICLE 7 – FEES, ROYALTIES AND

PAYMENTS.

 

7.1.          Research

Program Fees.  GNE shall

pay to SGI the following amounts in consideration of the Research Program:

 

7.1.1        Within

thirty (30) days of the Effective Date, GNE shall pay to SGI the sum of Two

Million Five Hundred Thousand Dollars ($2,500,000.00) by wire transfer of

immediately available funds (the “ADC Access Fee”).

 

7.1.2        If

GNE elects to acquire more than [***] Options pursuant to Section 2.1.2, GNE

shall make an additional payment in the sum of [***] for [***] by wire transfer

of immediately available funds, which payment shall be due within [***]

following notice by SGI to GNE that [***],

as set forth in Section 2.1.3 (the “Additional ADC Access Fee”).  In addition, if GNE wishes to [***] to [***] during the [***], GNE

shall pay to SGI [***] of the [***] GNE wishes to [***] to have the [***] to

[***] (“Designation Renewal Fees”). 

Furthermore, for Research Antigens requested and granted during the

First Research Program Renewal Term, the Additional ADC Access shall increase

by [***] per Research Antigen.

 

7.1.3        If

GNE [***], then GNE shall pay to

SGI on the first day of [***] GNE wishes to [***] (the “Research Fees”); provided, however,

that GNE shall not [***] a [***]

for a [***] if either: (a) [***]  such [***] has been [***] (i.e., an

[***]); or (b) GNE [***] for such [***] during the [***], as the case may be,

that is being [***].

 

14

 

7.1.4        GNE

shall pay SGI at an annual rate of [***] per [***] who [***] as

requested by GNE for the [***] of the Research Program plus the costs of

materials used by SGI in performing the Research Program (collectively the “[***]”), payable quarterly.  Commencing the [***] and every [***]

thereafter, the [***] will

increase by [***] per [***] per

year.  Within [***] after the end of

each [***], SGI shall submit a report to GNE supporting the calculation of [***] due for such Calendar Quarter (a

“[***]”).  GNE shall pay all [***] to SGI within [***] of receipt of each [***].  The Research Fees and [***]

shall be collectively referred to as the “Research Program Fees”.

 

7.2.          Option

Exercise Fee.

 

7.2.1.       Upon

the exercise of each Option pursuant to Section 4.2.2., GNE shall make a

payment to SGI in the sum of [***] by wire transfer of immediately available

funds (the “Option Exercise Fee”).

 

7.2.2.       GNE

may terminate the Exclusive License for any Exclusive Antigen for any reason

and at any time immediately upon written notice to SGI; provided that SGI will

retain the Option Exercise Fee.  The

Exclusive License for such Exclusive Antigen shall terminate effective as of

such termination date.

 

7.3.          Royalties

Payable by GNE.

 

In consideration for the Exclusive Licenses granted to

GNE herein, during the Royalty Term, GNE shall pay to SGI royalties on Net Sales

of Licensed Products.  Such royalties

shall be established at the following rates, determined on a Licensed

Product-by-Licensed Product basis as set forth below.

 

7.3.1        For

[***] for which the [***] would [***]

of [***]:

 

7.3.1.1     [***]

of the first [***] in aggregate [***] of the [***] in each [***];

 

7.3.1.2     [***]

of incremental aggregate [***] of the [***] in excess of [***] up to [***] in

each [***]; and

 

7.3.1.3     [***]

of incremental aggregate [***] of the [***] in excess of [***] in each [***].

 

7.3.2        For

[***] for which the [***] would [***] any [***] of [***]:

 

7.3.2.1     [***]

of the first [***] in aggregate [***] of the [***] in each [***];

 

7.3.2.2     [***]

of incremental aggregate Net Sales of the [***] in excess of [***] up to [***]

in each [***]; and

 

7.3.2.3     [***]

of incremental aggregate Net Sales of the [***] in excess of [***] in each

[***].

 

15

 

7.3.3        Notwithstanding

the foregoing Sections 7.3.1 and 7.3.2, in the event the [***] of a [***] would

[***] any [***] of [***], but a

[***] containing one or more [***] which would [***] is [***], GNE shall as of

the date such [***] is [***] and [***]

in the [***] herein [***].

 

7.4.          Third-Party

Royalties.

 

7.4.1.       GNE

shall pay any Third-Party royalties owed on account of its sales of Licensed

Product in the Licensed Territory, including royalties owed due to use of the

SGI Technology; [***].  SGI represents

and warrants that [***]

 

7.4.2.       If

the [***] to [***] under [***] and to [***]

for the [***]  the following [***]:

[***]  for [***], [***] for [***]

in the [***] and [***] for [***]

in the [***], then the [***]

hereunder shall be [***] to

[***] of the [***]; provided,

however, that in no event shall the [***] under this Agreement be [***] of the [***]

under this Agreement.  The [***] under  [***]  shall be [***] to [***] of the [***]  to [***] for the [***];

provided, however, that in no event shall the [***]  under

this Agreement [***]  of the [***] that would [***]

under this Agreement.

 

7.4.3        An

appropriate [***]  with one or more [***]  shall

be mutually agreed upon, in good faith, by the Parties [***].

 

7.5.          Milestone

Payments.

 

As additional consideration for the licenses, rights

and privileges granted to it hereunder, GNE shall pay to SGI the following

milestone payments to SGI within [***] of the first occurrence of each event

set forth below with respect to the first Licensed Product for each Exclusive

Antigen, whether such events are achieved by GNE, its Affiliates or

Sublicensees:

 

7.5.1        Upon

[***];

 

7.5.2        Upon

[***];

 

7.5.3        Upon

[***];

 

7.5.4        Upon

[***];

 

7.5.5        Upon

[***]; and

 

7.5.6        Upon

[***].

 

GNE will only be required to pay each of the above

milestones to SGI for the first Licensed Product for each Exclusive Antigen to

complete the milestone event and each milestone will only be paid once for any

Exclusive Antigen.

 

16

 

7.6.          Payment

Terms.

 

Royalties shown to have accrued by each Report

provided for under Article 8 of this Agreement shall be due on the date such

Report is due.  Payment of royalties in

whole or in part may be made in advance of such due date.

 

7.7.          Payment

Method.

 

All payments by GNE to SGI under this Agreement shall

be paid in U.S. dollars, and all such payments shall be made by bank wire

transfer in immediately available funds to the bank account designated by SGI

in writing.

 

7.8.          Exchange Control.

 

If at any time legal restrictions prevent the prompt

remittance of part or all royalties with respect to any country in the

Territory where Licensed Product is sold, payment shall be made through such

lawful means or method as the Parties reasonably shall determine.

 

7.9.          Withholding Taxes.

 

Except as otherwise provided below, all amounts owing

from GNE to SGI under this Agreement are gross amounts.  GNE shall be entitled to deduct the amount

of any withholding taxes payable or required to be withheld by GNE, its

Affiliates or Sublicensees, to the extent GNE, its Affiliates or Sublicensees

pay to the appropriate governmental authority on behalf of SGI such taxes.  GNE shall use commercially reasonable

efforts to minimize any such taxes, levies or charges required to be withheld

on behalf of SGI by GNE, its Affiliates or Sublicensees.  GNE promptly shall deliver to SGI proof of

payment of all such taxes, levies and other charges, together with copies of

all communications from or with such governmental authority with respect

thereto.

 

ARTICLE 8 - ROYALTY REPORTS AND

ACCOUNTING

 

8.1.          Reports,

Exchange Rates.

 

8.1.1.       During

the Royalty Term, GNE shall furnish to SGI, with respect to each Calendar

Quarter, a written report showing on a consolidated basis in reasonably

specific detail and on a country-by-country basis, (a) the gross sales of

Licensed Products sold by GNE, its Affiliates and its Sublicensees in the

Territory during the corresponding Calendar Quarter and the calculation of Net

Sales from such gross sales; (b) the royalties payable in U.S. dollars, if

any, which shall have accrued hereunder based upon Net Sales of Licensed

Products; (c) the withholding taxes, if any, required by law to be

deducted in respect of such royalties; (d) the dates of the First

Commercial Sale of each Licensed Product in each country in the Territory if it

has occurred during the corresponding Calendar Quarter; and (e) the

exchange rates (as

 

17

 

determined pursuant to Section 8.1.4 herein) used in determining the

royalty amount expressed in U.S. dollars (collectively, “Reports”).

 

8.1.2.       GNE

shall include in each permitted sublicense granted by it pursuant to this

Agreement a provision requiring its Affiliates and Sublicensees to make Reports

to GNE within [***] of the close of each Calendar Quarter and to keep and

maintain records of sales made pursuant to such sublicense.

 

8.1.3.       Reports

shall be due on the [***] following the close of each Calendar Quarter.  GNE shall keep complete and accurate records

in sufficient detail to properly reflect all gross sales and Net Sales and to

enable the royalties payable hereunder to be determined.

 

8.1.4.       With

respect to sales (if any) of Licensed Products invoiced in U.S. dollars, the

gross sales, Net Sales, and royalties payable shall be expressed in U.S.

dollars.  With respect to sales of

Licensed Products invoiced in a currency other than U.S. dollars, the gross

sales, Net Sales and royalties payable shall be expressed in the currency of

the invoice issued by the Party making the sale together with the U.S. dollars

equivalent of the royalty payable, calculated using the [***].

 

8.2.          Audits.

 

8.2.1.       Upon

the written request of SGI and with at least [***] prior written notice, but

not more than once in each [***],

GNE shall permit an independent certified public accounting firm of

internationally recognized standing, selected by SGI and reasonably acceptable

to GNE, at SGI’s expense, to have access during normal business hours to such

of the records of GNE as required to be maintained under this Agreement to

verify the accuracy of the Reports hereunder for any year ending not more than

[***] prior to the date of such request. 

The accounting firm shall disclose to SGI only whether the records are

correct or not and the specific details concerning any discrepancies.  No other information shall be shared.

 

8.2.2.       If

such accounting firm concludes that additional royalties were owed during such

period, GNE shall pay the additional royalties within [***] of the date SGI

delivers to GNE such accounting firm’s written report so concluding.  The fees charged by such accounting firm

shall be paid by SGI; provided, however, if the audit discloses

that the royalties payable by GNE for the audited period are more than [***] of

the royalties actually paid for such period, then GNE shall pay the reasonable

fees and expenses charged by such accounting firm. If such accounting firm

concludes that the royalties paid were more than what was owed during such

period, SGI shall refund the overpayments within [***] of the date SGI receives

such accounting firm’s written report so concluding.

 

8.2.3.       GNE

shall include in each permitted sublicense granted by it pursuant to the

Agreement a provision requiring its Affiliates and Sublicensees to make reports

to GNE and to keep and maintain records of sales made pursuant to such

sublicense.

 

18

 

8.2.4        Upon

the expiration of [***] following the end of any calendar year, the calculation

of royalties payable with respect to such year shall be binding and conclusive

upon SGI, and GNE, its Affiliates and Sublicensees shall be released from any

liability or accountability with respect to royalties for such year.

 

8.3.          Confidential Financial Information.

 

SGI shall treat all financial information subject to

review under this Article 8 or under any sublicense agreement as Confidential

Information of GNE as set forth in Article 9, and shall cause its accounting

firm to retain all such financial information in confidence under terms

substantially similar to those set forth in Article 9.

 

ARTICLE 9 – CONFIDENTIALITY

 

9.1           Non-Disclosure

Obligations.

 

Except as otherwise provided in this Article 9, during

the Term and for a period of [***] thereafter, each Party shall maintain in

confidence, and use only for purposes as expressly authorized and contemplated

by this Agreement, all confidential or proprietary information, data, documents

or other materials supplied by the other Party under this Agreement and marked

or otherwise identified as “Confidential,” including SGI Know-How, Drug

Conjugation Technology, Improvements and [***] and information relating to SGI’s and GNE’s respective

research programs, development, marketing and other business practices and

finances.  For purposes of this

Agreement, information and data described above shall be hereinafter referred

to as “Confidential Information.” 

Each Party shall use at least the same standard of care as it uses to

protect its own Confidential Information to ensure that its and its Affiliates’

employees, agents, consultants and clinical investigators only make use of the

other Party’s Confidential Information for purposes as expressly authorized and

contemplated by this Agreement and do not disclose or make any unauthorized use

of such Confidential Information.

 

9.2.          Permitted

Disclosures.

 

Notwithstanding the foregoing, the provisions of

Section 9.1 hereof shall not apply to information, documents or materials that

the receiving Party can conclusively establish:

 

(a)           have

become published or otherwise entered the public domain other than by wrongful

acts of the receiving Party or its Affiliates in contravention of this

Agreement;

 

(b)           are

permitted to be disclosed by prior consent of the other Party;

 

(c)           have

become known to the disclosing Party by a Third-Party, provided such

Confidential Information was not obtained by such Third-Party directly or

indirectly from the other Party under this Agreement on a confidential basis;

 

19

 

(d)           prior

to disclosure under the Agreement, was already in the possession of the

receiving Party, its Affiliates or Sublicensees, provided such Confidential

Information was not obtained directly or indirectly from the other Party under

this Agreement;

 

(e)           is

disclosed in a press release agreed to by both Parties hereto, which agreement

shall not be unreasonably withheld; and

 

(f)            are

required to be disclosed by the receiving Party to comply with any applicable

law, regulation or court order, or are reasonably necessary to obtain patents,

copyrights or authorizations to conduct clinical trials with, and to commercially

market Licensed Product(s), provided that the receiving Party shall provide

prior notice of such disclosure to the other Party and take reasonable and

lawful actions to avoid or minimize the degree of disclosure.

 

In addition, GNE shall be permitted to disclose SGI’s

Confidential Information:

 

(g)           to

the extent reasonably needed in a patent application claiming Program

Inventions made hereunder  to be filed

with the United States Patent and Trademark Office and/or any similar foreign

agency, provided that GNE shall provide prior notice of such disclosure to SGI

and take reasonable and lawful actions to avoid or minimize the degree of

disclosure;

 

(h)           to

a sublicensee as permitted hereunder, provided that such sublicensee be subject

to obligations of confidentiality substantially similar to those contained

herein; and

 

(i)            to

a bona fide collaborator or manufacturing, development or sales partner, but

only to the extent directly relevant to the collaboration or partnership and

provided that such collaborator or partner be subject to obligations of

confidentiality substantially similar to those contained herein.

 

9.3.          Terms of

the Agreement.

 

GNE and SGI shall not disclose any terms or conditions

of this Agreement to any Third-Party without the prior consent of the other

Party, except as required by applicable laws, regulations or a court order (and

in any such case the disclosing Party shall provide notice to the other Party

and takes reasonable and lawful actions to avoid or minimize the degree of such

disclosures).

 

9.4.          Press

Releases and Other Disclosures to Third-Parties.

 

Neither SGI nor GNE will, without the prior consent of

the other, issue any press release or make any other public announcement or

furnish any statement to any Person (other than either Parties’ respective

Affiliates) concerning the existence of this Agreement, its terms and the

transactions contemplated thereby, except for (i) an initial press release

mutually agreed upon by the Parties, (ii) disclosures made in compliance with

Sections 9.2 and 9.3 hereof, (iii) attorneys,

 

20

 

consultants, and accountants retained to represent them in connection

with the transactions contemplated hereby.

 

9.5.          Publications

Regarding Results of the Research Program.

 

Neither Party may publish, present or announce results

of the Research Program either orally or in writing (a “Publication”)

without complying with the provisions of this Section 9.5.  The other Party shall have [***] (or such

lesser amount of time as a specific situation may allow) from receipt of a

proposed Publication to provide comments and/or proposed changes to the

publishing Party.  The publishing Party

shall take into account the comments and/or proposed changes made by the other

Party on any Publication and shall agree to have employees or others acting on

behalf of the other Party be mentioned as appropriate as co-authors on any

Publication describing results to which such persons have contributed.  If the other Party reasonably determines the

Publication would amount to the public disclosure of such Party’s Confidential

Information and/or of a patentable invention upon which a patent application

should be filed prior to any such disclosure, submission of the concerned

Publication to Third-Parties shall be delayed for such period as may appear

reasonably necessary for appropriately deleting Confidential Information from

the proposed Publication and/or drafting and filing a patent application

covering such invention provided such period does not exceed [***] from the

date the publishing Party first provided the proposed Publication to the other

Party.

 

ARTICLE 10 - INVENTIONS AND PATENTS

 

10.1.        Ownership

of Inventions.

 

10.1.1.     Disclosure

of Inventions.  Each

Party shall promptly disclose to the other Party the making, conception or

reduction to practice of any inventions directly arising out of the Research

Program (“Program Inventions”).

 

10.1.2      Ownership

of Program Inventions.  All

right, title and interest in all Program Inventions that are discovered, made

or conceived as part of the activities conducted pursuant to this Agreement

during the Research Program Term shall be owned as follows:

(a)           [***] shall own all Program

Inventions that (i) are invented solely by one or more employees, agents or

consultants of [***] and/or any [***] pursuant to this Agreement and do not [***]; or (ii) [***], and to the extent that any such [***] within Program

Inventions shall have been invented by [***] and are owned by [***], [***]

hereby assigns all of its rights, title and interest therein to [***];

 

(b)           [***] shall own all Program

Inventions that (i) are invented solely by one or more employees, agents or

consultants of [***], excluding any [***] pursuant to this Agreement and do not

[***]; or (ii) [***], and to the extent that any such

[***] within Program Inventions shall have been invented by [***] and is owned

by [***], [***] hereby assigns all of its rights, title and interest therein to

[***]; and

 

21

 

(c)           Except as set forth in Sections

10.1.2(a) and 10.1.2(b), [***] and [***] shall [***] own all other Program

Inventions.

 

Inventorship shall

be determined under U.S. patent law.  In

the event of a dispute regarding inventorship, the Parties shall engage a Third

Party patent attorney jointly selected by the Parties to resolve such dispute.

 

10.2.        Patent

Prosecution and Maintenance.

 

10.2.1.     SGI shall be responsible for and shall

control the preparation, filing, prosecution, grant and maintenance of all

Licensed Patents.  SGI shall, at its

sole expense, prepare, file, prosecute and maintain such Licensed Patents in

good faith consistent with its customary patent policy and its reasonable

business judgment, and shall consider in good faith the interests of GNE in so

doing.

 

10.2.2.     Each Party shall be responsible for and

shall control the preparation, filing, prosecution, grant and maintenance, of

any patents and patent applications claiming Program Inventions owned solely by

it in accordance with Section 10.1 and shall, at its sole expense, prepare,

file, prosecute and maintain such patent rights in good faith consistent with

its customary patent policy and its reasonable business judgment.  Patents and patent applications claiming

Program Inventions owned jointly by both Parties in accordance with Section

10.1 (“Joint Patents”) shall be controlled, prepared, filed, prosecuted

and maintained by an outside legal firm mutually agreed to between the Parties,

under the equal direction and control of both Parties.  The cost of such outside legal expenses

shall be evenly borne by the Parties.

 

10.2.3.     The Parties shall at all times fully

cooperate in order to reasonably implement the foregoing provisions, such

cooperation may include without limitation the execution of necessary legal

documents.

 

10.3.        Enforcement

of Licensed Patents.

 

10.3.1.     SGI shall have the right, at its sole

expense, to determine the appropriate course of action to enforce the Licensed

Patents or otherwise abate the infringement thereof, to take (or refrain from

taking) appropriate action to enforce the Licensed Patents, to control any

litigation or other enforcement action and to enter into, or permit, the

settlement of any such litigation or other enforcement action with respect to

the Licensed Patents, and in good faith shall consider the interests of GNE in

so doing.  All monies recovered upon the

final judgment or settlement of any such suit to enforce any Licensed Patents

shall be allocated first to SGI to the extent necessary to compensate it for

its expenses in its enforcement, second to GNE to the extent necessary to

compensate it for its expenses in cooperating with SGI in its enforcement, and

finally prorated in accordance with the damages for which such judgment or

settlement is reasonably intended to compensate.  GNE and SGI shall fully cooperate with each other in any action

to enforce the Licensed Patents.  If SGI

fails to take any action to enforce the Licensed Patents or control any

litigation with respect to the Licensed Patents within a period of [***] bring

and control any such action by counsel of its own choice, and in such case, all

monies

 

22

 

recovered upon the final judgment or settlement of any such suit to

enforce any Licensed Patents shall be retained by GNE allocated first to GNE to

the extent necessary to compensate it for its expenses in its enforcement,

second to SGI to the extent necessary to compensate it for its expenses in

cooperating with GNE in its enforcement, and finally prorated in accordance

with the damages for which such judgment or settlement is reasonably intended

to compensate.  In such a case, SGI

shall cooperate fully with GNE, at GNE’s expense, in its efforts to enforce the

Licensed Patents, including being joined as a party to such action if

necessary.

 

10.3.2.     GNE shall have the right, at its sole

expense, to determine the appropriate course of action to enforce the patents

claiming Program Inventions owned solely by GNE in accordance with Section 10.1

(“GNE Patents”) or otherwise abate the infringement thereof, to take (or

refrain from taking) appropriate action to enforce the GNE Patents, to control

any litigation or other enforcement action and to enter into, or permit, the

settlement of any such litigation or other enforcement action with respect to

the GNE Patents.  All monies recovered

upon the final judgment or settlement of any such suit to enforce any GNE

Patents shall be retained by GNE.  SGI

and GNE shall fully cooperate with each other in any action to enforce the GNE

Patents.

 

10.3.3      In the event either Party becomes aware of

an Infringement by a Third Party of a Joint Patent, it shall promptly notify

the other Party and the Parties shall determine a mutually agreeable course of action.

 

10.4.        Prior

Patent Rights. 

Notwithstanding anything to the contrary in this Agreement, with respect

to any Licensed Patents that are subject to the SGI In-Licenses, the rights and

obligations of the Parties under Section 10.2 and 10.3 shall be subject to

SGI’s licensors’ rights to participate in and control prosecution, maintenance

and enforcement of such Licensed Patents in accordance with the terms and

conditions of the applicable SGI In-License.

 

ARTICLE 11 - INFRINGEMENT ACTIONS

BROUGHT BY THIRD-PARTIES

 

If GNE, SGI or their respective Affiliates, or GNE’s

Sublicensees, is sued by a Third-Party for infringement of a Third-Party’s

patent because of the use of the Drug Conjugation Technology, the Party which

has been sued shall promptly notify the other Party, in no event later than

[***] of the institution of such suit. 

The notice shall set forth the facts of such infringement and provide

evidence of such infringement that is within the notifying Party’s control.  The Parties shall then meet to discuss each

Party’s commercial interests in the defense of the suit, a plan for the defense

of the suit, how the costs of the suit should be allocated, and who should have

primary control of the suit.  In no

event may the Party controlling the suit settle or otherwise consent to an

adverse judgment in such suit that diminishes the rights or interests of the

non-controlling Party without the express written consent of the

non-controlling Party.

 

23

 

ARTICLE 12 - REGULATORY ASSISTANCE

 

Should GNE develop an ADC for clinical development,

SGI will provide at GNE’s request, technical information reasonably required

for GNE to file for and obtain permission to commence human clinical trials

including, without limitation, information relating to the ADC, the toxin used,

the linker used and the linker conjugated to the toxin.  This information will include, as available,

Chemistry Manufacturing and Controls documentation, other toxicity and safety

data, access to any drug master files on record with the FDA (and/or other

similar foreign authorities) and any other relevant materials.  GNE shall reimburse SGI for any

out-of-pocket costs incurred by SGI in providing such information plus an

amount equal to SGI’s then current [***],

as set forth in Section 7.1.4.

 

ARTICLE 13 – REPRESENTATIONS AND

WARRANTIES

 

13.1.        Representations and Warranties.

 

13.1.1.           This

Agreement has been duly executed and delivered by each Party and constitutes

the valid and binding obligation of each Party, enforceable against such Party

in accordance with its terms, except as enforceability may be limited by

bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium or

other laws relating to or affecting creditors’ rights generally and by general

equitable principals.  The execution,

delivery and performance of this Agreement has been duly authorized by all

necessary action on the part of each Party, its officers and directors.

 

13.1.2.           The

execution, delivery and performance of the Agreement by each Party does not

conflict with any agreement, instrument or understanding, oral or written, to

which it is a party or by which it is bound, nor violate any law or regulation

of any court, governmental body or administrative or other agency having

jurisdiction over it.

 

13.1.3.           SGI

has not, and during the term of the Agreement will not, grant any right to any

Third-Party relating to the Licensed Patents and SGI Know-how which would

conflict with the rights granted to GNE hereunder.

 

13.1.4.           SGI

represents and warrants that it has the right to grant the licenses granted

herein and that it has no knowledge of any rights of any Third-Parties that

would interfere with the practice of the Licensed Patents or other SGI

Technology.

 

13.1.5.           SGI

represents and warrants that it will perform all of its obligations hereunder

in a professional and good workman like manner.

 

13.2.        Performance by Affiliates.

 

The Parties recognize that each may perform some or

all of its obligations under this Agreement through Affiliates, provided,

however, that each Party shall remain responsible and be guarantor of

the performance by its Affiliates and shall cause its Affiliates to comply with

the provisions of this Agreement in connection with such performance.

 

24

 

ARTICLE 14 – TERM AND TERMINATION

 

14.1.        Term.

 

Unless earlier terminated pursuant to this Article 14,

the term of this Agreement (the “Term”) shall commence on the Effective

Date and shall remain in full force and effect until the earlier of (a) the

expiration of the Research Program Term unless GNE exercises at least one (1)

Option prior to such date; or (b) the expiration of the last to expire Royalty

Term.

 

14.2.        Termination

by GNE.

 

GNE shall have the right, at any time, to terminate

this Agreement as a whole by providing not less than [***] prior written notice

to SGI of such termination; provided that termination by GNE under this

Section 14.2 shall not relieve GNE of its obligation to pay [***] for the remainder of the then

current [***] pursuant to

Sections 3.5 and 7.1.4.

 

14.3.        Termination

of License to Specific Research Antigen or Exclusive Antigen by GNE.

 

GNE shall have the right at any time to terminate its

rights to any specific Research Antigen or Exclusive Antigen immediately upon

written notice to SGI of such termination, whereupon GNE’s license with respect

to such Research Antigen or Exclusive Antigen shall automatically terminate and

all rights granted under this Agreement specifically related to the use of SGI

Technology in connection with the Research Antigen or Exclusive Antigen shall

revert back to SGI.

 

14.4.        Termination

for Cause.

 

Either Party may terminate this Agreement for material

breach by the other Party (the “Breaching Party”) of any material

provision of the Agreement, if the Breaching Party has not cured such breach

within [***] after notice thereof; provided, however, that

neither Party shall be deemed to be in material breach of this Agreement for

purposes of a termination hereunder during any period in which a good faith

dispute between the Parties exists regarding performance of breach of its

obligations hereunder.

 

14.5.        Termination

Upon Insolvency.

 

Either Party may terminate this Agreement if, at any

time, the other Party shall file in any court or agency pursuant to any statute

or regulation of any state, country or jurisdiction, a petition in bankruptcy

or insolvency or for reorganization or for an arrangement or for the

appointment of a receiver or trustee of that Party or of its assets, or if such

other Party proposes a written agreement of composition or extension of its

debts, or if such other Party shall be served with an involuntary petition

against it, filed in any insolvency proceeding, and such petition shall not be

dismissed within [***] after the filing thereof, or if such other Party shall

propose or be a 

 

25

 

party to any dissolution or liquidation, or if such other Party shall

make an assignment for the benefit of its creditors.

 

14.6.        Termination

of SGI In-Licenses.  All

rights and obligations under an SGI In-License sublicensed under this Agreement

shall terminate upon [***] prior written notice by SGI if GNE breaches any

material provision of such SGI In-License Agreement and fails to cure such

breach within [***] period; provided, however such cure period may be extended

by consent of the Parties.  All rights

and obligations under the [***]

shall automatically terminate if GNE fails to [***].  SGI covenants that it will use reasonable commercial efforts to

maintain all SGI In-Licenses for the duration of this Agreement.  In the event, despite such efforts, any SGI

In-License(s) terminates, (a) SGI hereby grants to GNE whatever rights it can

grant under such SGI In-License(s) to enable GNE to continue enjoying all

rights it had thereunder and (b) the Parties shall reduce the payments due to

SGI hereunder by such appropriate amounts as to reflect the loss in value to

GNE based on the termination of the SGI In-License(s).

 

14.7.        Effect of

Expiration and Termination.

 

14.7.1.    

Except where explicitly provided within this Agreement, termination of this

Agreement for any reason, or expiration of this Agreement, will not affect any:

(i) obligations, including payment of any royalties or other sums which have

accrued as of the date of termination or expiration, and (ii) rights and

obligations which, from the context thereof, are intended to survive

termination or expiration of this Agreement, including provisions of Articles 1,

9, 10, 11, 15, 19 and 20, Sections 4.5, 8.2, 8.3 and 14.7 and any payment

obligations pursuant to Section 7 incurred prior to termination, which shall

survive the expiration or termination of the Agreement.  Notwithstanding the foregoing, all licenses

granted by SGI to GNE hereunder, including all Exclusive Licenses, and all

sublicenses granted by GNE hereunder, will immediately terminate upon

termination of this Agreement pursuant to Sections 14.1(a), 14.2, 14.4 or 14.5.

 

14.7.2.      Upon

the expiration of the Royalty Term for each Exclusive Antigen, SGI shall grant,

and shall by this provision be deemed to have granted, to GNE a royalty-free,

perpetual, worldwide, license to use the SGI Technology for that Exclusive

Antigen with no further obligation to SGI.

 

ARTICLE 15 - INDEMNITY

 

15.1.        Direct

Indemnity.

 

15.1.1.      Each

Party shall indemnify and hold harmless, and hereby forever releases and

discharges the other Party from and against all claims, demands, liabilities,

damages and expenses, including attorneys’ fees and costs (collectively, the “Liabilities”)

arising out of (i) the breach of any material provision of this Agreement by

the indemnifying Party (or the inaccuracy of any representation or warranty

made by such Party in this Agreement), except to the extent such Liabilities

resulted from the gross negligence, recklessness or willful misconduct of the

 

26

 

other Party; or (ii) the gross negligence, recklessness or willful

misconduct of the indemnifying Party in connection with the performance of its

obligations hereunder.

 

15.1.2.      GNE

shall indemnify and hold harmless, and hereby forever releases and discharges

SGI from and against all Liabilities suffered or incurred arising out of any

Third-Party claims for personal injury, death or disability or any product

recall to the extent caused by (a) any failure to test for or provide adequate

warnings of adverse side effects to the extent such failure arises out of acts

or omissions in connection with the preclinical or clinical testing of any

Licensed Product, (b) any manufacturing defect in any Licensed Product or (c)

any other act or omission of GNE in connection with its obligations under this

Agreement; except in each case to the extent such Liabilities resulted from the

gross negligence, recklessness or willful misconduct by SGI or the inaccuracy

of any representation or warranty made by SGI in this Agreement.

 

15.1.3.      SGI

shall indemnify and hold harmless, and hereby forever releases and discharges

GNE from and against all Liabilities suffered or incurred arising out of any

Third-Party claims for personal injury, death or disability or any product

recall to the extent caused by (a) any SGI Technology incorporated in a product

other than a GNE Licensed Product, (b) any manufacturing defect in any SGI

Technology or other materials provided by SGI to GNE, or (c) any other act or

omission of SGI in connection with its obligations under this Agreement; except

in each case to the extent such Liabilities resulted from the gross negligence,

recklessness or willful misconduct by GNE or the inaccuracy of any

representation or warranty made by GNE in this Agreement.

 

15.2         Procedure.

 

A Party (the “Indemnitee”) that intends to

claim indemnification under this Article 15 shall promptly provide notice

to the other Party (the “Indemnitor”) of any Liability or action in

respect of which the Indemnitee intends to claim such indemnification, which

notice shall include a reasonable identification of the alleged facts giving rise

to such Liability, and the Indemnitor shall have the right to participate in,

and, to the extent the Indemnitor so desires, jointly with any other Indemnitor

similarly noticed, to assume the defense thereof with counsel selected by the

Indemnitor; provided, however, that the Indemnitee shall have the

right to retain its own counsel, with the fees and expenses to be paid by the

Indemnitor, if representation of such Indemnitee by the counsel retained by the

Indemnitor would be inappropriate due to actual or potential differing

interests between such Indemnitee and any other Party represented by such

counsel in such proceedings.  Any

settlement of a Liability for which any Indemnitee seeks to be reimbursed,

indemnified, defended or held harmless under this Article 15 shall be subject

to prior consent of such Indemnitee, such consent shall be withheld

unreasonably

 

ARTICLE 16 - FORCE MAJEURE

 

No Party (or any of its Affiliates) shall be held

liable or responsible to the other Party (or any of its Affiliates) nor be

deemed to have defaulted under or breached the Agreement for failure or delay

in fulfilling or performing any term of the Agreement when such failure or

delay is caused by or results from causes beyond the reasonable control of the

affected Party (or any of its Affiliates) including fire, floods, embargoes,

war, acts of war (whether war be declared or 

 

27

 

not), insurrections, riots, civil commotions, acts of God or acts, or

omissions or delays in acting by any governmental authority (collectively, “Events

of Force Majeure”); provided, however, that the affected

Party shall exert all reasonable efforts to eliminate, cure or overcome any

such Event of Force Majeure and to resume performance of its covenants with all

possible speed.  Notwithstanding the

foregoing, to the extent that an Event of Force Majeure continues for a period

in excess of [***], the affected Party shall promptly notify in writing the

other Party of such Event of Force Majeure and within [***] of the other

Party’s receipt of such notice, the Parties agree to negotiate in good faith

either (i) to resolve the Event of Force Majeure, if possible, (ii) to extend

by mutual agreement the time period to resolve, eliminate, cure or overcome such

Event of Force Majeure, (iii) to amend this Agreement to the extent reasonably

possible, or (iv) to terminate this Agreement.

 

ARTICLE 17 - ASSIGNMENT

 

This Agreement may not be assigned or otherwise

transferred, nor, except as expressly provided hereunder, may any right or

obligations hereunder be assigned or transferred to any Third-Party by either

Party without the consent of the other Party, such consent not to be

unreasonably withheld; provided, however, that either Party may,

without such consent but with notification, assign this Agreement and its

rights and obligations hereunder to any of its Affiliates or in connection with

the transfer or sale of all or substantially all of its business, or in the

event of its merger or consolidation (such merger or consolidation shall be

hereinafter referred to as a “Change in Control”).  Any permitted assignee shall assume all

rights and obligations of its assignor under this Agreement; [***].

 

ARTICLE 18 - SEVERABILITY

 

Each Party hereby agrees that it does not intend to

violate any public policy, statutory or common laws, rules, regulations, treaty

or decision of any government agency or executive body thereof of any country

or community or association of countries. 

Should one or more provisions of this Agreement be or become invalid,

the Parties hereto shall substitute, by mutual consent, valid provisions for

such invalid provisions which valid provisions in their economic effect are

sufficiently similar to the invalid provisions that it can be reasonably assumed

that the Parties would have entered into this Agreement with such provisions.

 

In case such provisions cannot be agreed upon, the

invalidity of one or several provisions of this Agreement shall not affect the

validity of this Agreement as a whole, unless the invalid provisions are of

such essential importance to this Agreement that it is to be reasonably assumed

that the Parties would not have entered into this Agreement without the invalid

provisions.

 

ARTICLE 19 – INSURANCE

 

During the term of this Agreement

and thereafter for the period of time required below, each Party shall maintain

on [***].  Commencing not later than

[***] and thereafter for the period of time required below, the parties shall

obtain and maintain on an ongoing basis [***] (including [***] to cover the

[***] under this Agreement subject to the terms and conditions of the insurance

policies) in the following amounts:

 

28

 

GNE: at least [***].  All of such insurance coverage shall be maintained with insurance

companies having an [***] or better.

 

SGI: at least [***].  All of such insurance coverage shall be maintained with insurance

companies having an [***]  or better.

 

The aggregate deductibles

under both parties’ [***] insurance shall not exceed [***] and the deductibles

under both parties’ [***] insurance shall be satisfactory to both parties.  The insurance coverages carried by each

party shall be primary, and each party shall name the other party as an

additional insured under their respective insurance policies, but only with

respect to their own obligations under this Agreement.  In addition, GNE shall name [***] as an

additional insured under GNE’s insurance policies with respect to the [***].  Each party shall provide a notice to the

other party at least [***] to any cancellation or material change in insurance

coverage.

 

Not later than the effective

date of this Agreement with respect to the [***] coverage, and not later than

[***] prior to the [***] with respect to the [***] coverage, the parties shall

provide to each other a certificate(s) evidencing all such required coverage

hereunder.  Thereafter the parties shall

maintain such insurance coverage without interruption during the term of this

Agreement and for a period of at least [***] after the expiration or

termination of the term and shall provide certificates evidencing such

insurance coverage without interruption on an annual basis (by no later than

the annual renewal date for such coverage) during the period of time for which

such coverage must be maintained.

 

ARTICLE 20 - MISCELLANEOUS

 

20.1.        Notices.

 

Any consent, notice or report required or permitted to

be given or made under this Agreement by one of the Parties hereto to the other

shall be in writing, delivered personally or by facsimile (and promptly

confirmed by personal delivery, first class air mail or courier), first class

air mail or courier, postage prepaid (where applicable), addressed to such

other Party at its address indicated below, or to such other address as the

addressee shall have last furnished in writing to the address or in accordance

with this Section 20.1 and (except as otherwise provided in this Agreement)

shall be effective upon receipt by the addressee.

 

If to SGI:

Seattle Genetics, Inc.

21823 30th Drive S.E.

Bothell, WA 98021

Attention:  Chief Executive Officer

 

With copy to:

Venture Law Group

4750 Carillon Point

29

 

Kirkland, WA 

98033

Attention:  Sonya F. Erickson

 

If to GNE:

Genentech, Inc.

1 DNA Way

South San Francisco, CA  94080

Attention:  Vice President, Research

 

With copy to:

Genentech, Inc.

1 DNA Way

South San Francisco, CA  94080

Attention:  Corporate Secretary

 

20.2.        Applicable

Law.

 

The Agreement shall be

governed by and construed in accordance with the laws of the State of

Washington, without regard to the conflict of law principles thereof.

 

20.3.        Dispute Resolution.

 

The Parties agree that if

any dispute or disagreement arises between GNE on the one hand and SGI on the

other in respect of this Agreement, they shall follow the following procedure

in an attempt to resolve the dispute or disagreement.

 

20.3.1.           The

Party claiming that such a dispute exists shall give notice in writing (“Notice

of Dispute”) to the other Party of the nature of the dispute;

 

20.3.2.           Within

[***] of receipt of a Notice of Dispute, a nominee or nominees of GNE and a

nominee or nominees of SGI shall meet in person and exchange written summaries

reflecting, in reasonable detail, the nature and extent of the dispute, and at

this meeting they shall use their reasonable endeavors to resolve the dispute;

 

20.3.3.           If,

within a further period of [***], the dispute has not been resolved, the

President of SGI and the President of GNE shall meet at a mutually agreed upon

time and location for the purpose of resolving such dispute;

 

20.3.4.           If,

within a further period of [***], the dispute has not been resolved or if, for

any reason, the required meeting has not been held, then the same shall be

submitted by the Parties to arbitration in Seattle, Washington in accordance

with the then-current commercial arbitration rules of the American Arbitration

Association (“AAA”) except as otherwise provided herein.  The Parties shall choose, by mutual

agreement, one (1) arbitrator within [***] of receipt of notice of the intent

to arbitrate.  If no arbitrator is

appointed within the times herein provided or any extension of time that is

mutually agreed upon, the AAA shall make such appointment within [***] of such

failure.  The judgment rendered by the

arbitrator shall include costs of 

 

30

 

arbitration, reasonable attorneys’ fees and reasonable costs for expert

and other witnesses.  Nothing in this

Agreement shall be deemed as preventing either Party from seeking injunctive

relief (or any other provisional remedy). 

If the issues in dispute involve scientific, technical or commercial

matters, any arbitrator chosen hereunder shall have educational training and/or

industry experience sufficient to demonstrate a reasonable level of relevant

scientific, medical and industry knowledge.

 

20.3.5.           In

the event of a dispute regarding any payments owing under this Agreement, all

undisputed amounts shall be paid promptly when due and the balance, if any,

promptly after resolution of the dispute.

 

20.4.        Entire

Agreement.

 

This Agreement contains the entire understanding of

the Parties with respect to the specific subject matter hereof.  All express or implied agreements and

understandings, either oral or written, heretofore made are expressly

superseded by this Agreement.  This

Agreement may be amended, or any term hereof modified, only by a written

instrument duly executed by both Parties hereto.

 

20.5.        Independent

Contractors.

 

SGI and GNE each acknowledge that they shall be

independent contractors and that the relationship between the two Parties shall

not constitute a partnership, joint venture, agency or any type of fiduciary

relationship.  Neither SGI nor GNE shall

have the authority to make any statements, representations or commitments of

any kind, or to take any action, which shall be binding on the other Party,

without the prior consent of the other Party to do so.

 

20.6.        Affiliates.

 

Each Party shall cause its respective Affiliates to

comply fully with the provisions of this Agreement to the extent such

provisions specifically relate to, or are intended to specifically relate to,

such Affiliates, as though such Affiliates were expressly named as joint

obligors hereunder.

 

20.7.        Waiver.

 

The waiver by either Party hereto of any right

hereunder or the failure to perform or of a breach by the other Party shall not

be deemed a waiver of any other right hereunder or of any other breach or

failure by said other Party whether of a similar nature or otherwise.

 

20.8.        Counterparts.

 

This Agreement may be executed in two or more

counterparts, each of which shall be deemed an original, but all of which

together shall constitute one and the same instrument.

 

31

 

IN WITNESS WHEREOF, the Parties have executed this

Agreement as of the date first set forth above.

 

	

   

  	

  SEATTLE

  GENETICS, INC.

  
	

   

  	

   

  
	

   

  	

  By:

  	

  /s/ Clay B. Siegall

  	

   

  
	

   

  	

   

  
	

   

  	

  Name:

  	

  Clay B. Siegall

  	

   

  
	

   

  	

   

  
	

   

  	

  Title:

  	

  President and CSO

  	

   

  
	

   

  	

   

  
	

   

  	

   

  
	

   

  	

  GENENTECH,

  INC.

  
	

   

  	

   

  
	

   

  	

  By: 

  	

  /s/ Arthur D. Levinson

  	

   

  
	

   

  	

   

  
	

   

  	

  Name:

  	

  Arthur D. Levinson

  	

   

  
	

   

  	

   

  
	

   

  	

  Title:

  	

  Chairman and Chief Executive Officer

  	

   

  
									

 

32

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]